<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">37868</article-id><article-id pub-id-type="doi">10.7554/eLife.37868</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Loss of p53 suppresses replication-stress-induced DNA breakage in G1/S checkpoint deficient cells</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-111481"><name><surname>Benedict</surname><given-names>Bente</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7503-8527</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-112553"><name><surname>van Harn</surname><given-names>Tanja</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-38936"><name><surname>Dekker</surname><given-names>Marleen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-112554"><name><surname>Hermsen</surname><given-names>Simone</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-112730"><name><surname>Kucukosmanoglu</surname><given-names>Asli</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-112556"><name><surname>Pieters</surname><given-names>Wietske</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-112560"><name><surname>Delzenne-Goette</surname><given-names>Elly</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-44949"><name><surname>Dorsman</surname><given-names>Josephine C</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-112559"><name><surname>Petermann</surname><given-names>Eva</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-66160"><name><surname>Foijer</surname><given-names>Floris</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-0989-3127</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-4887"><name><surname>te Riele</surname><given-names>Hein</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-0255-4042</contrib-id><email>h.t.riele@nki.nl</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Division of Tumor Biology and Immunology</institution><institution>The Netherlands Cancer Institute</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>The Netherlands</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Department of Clinical Genetics</institution><institution>VU University Medical Center</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>The Netherlands</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">School of Cancer Sciences</institution><institution>University of Birmingham</institution><addr-line><named-content content-type="city">Birmingham</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">European Research Institute for the Biology of Ageing</institution><institution>University Medical Center Groningen</institution><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>The Netherlands</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="senior_editor"><name><surname>Tyler</surname><given-names>Jessica K</given-names></name><role>Senior Editor</role><aff><institution>Weill Cornell Medicine</institution><country>United States</country></aff></contrib><contrib contrib-type="editor"><name><surname>Schlacher</surname><given-names>Katharina</given-names></name><role>Reviewing Editor</role><aff><institution>UT MD Anderson Cancer Center</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>16</day><month>10</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>7</volume><elocation-id>e37868</elocation-id><history><date date-type="received" iso-8601-date="2018-05-01"><day>01</day><month>05</month><year>2018</year></date><date date-type="accepted" iso-8601-date="2018-09-28"><day>28</day><month>09</month><year>2018</year></date></history><permissions><copyright-statement>© 2018, Benedict et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Benedict et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-37868-v2.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.37868.001</object-id><p>In cancer cells, loss of G1/S control is often accompanied by p53 pathway inactivation, the latter usually rationalized as a necessity for suppressing cell cycle arrest and apoptosis. However, we found an unanticipated effect of p53 loss in mouse and human G1-checkpoint-deficient cells: reduction of DNA damage. We show that abrogation of the G1/S-checkpoint allowed cells to enter S-phase under growth-restricting conditions at the expense of severe replication stress manifesting as decelerated DNA replication, reduced origin firing and accumulation of DNA double-strand breaks. In this system, loss of p53 allowed mitogen-independent proliferation, not by suppressing apoptosis, but rather by restoring origin firing and reducing DNA breakage. Loss of G1/S control also caused DNA damage and activation of p53 in an <italic>in vivo</italic> retinoblastoma model. Moreover, in a teratoma model, loss of p53 reduced DNA breakage. Thus, loss of p53 may promote growth of incipient cancer cells by reducing replication-stress-induced DNA damage.</p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.37868.002</object-id><title>eLife digest</title><p>Healthy cells go through a strictly regulated process called the cell cycle in order to divide. During this cycle the cell’s DNA is duplicated and the two copies are equally distributed between the two newly formed cells. Duplicating DNA is a complex procedure that can go wrong and damage the DNA. This damage, in turn, can cause cells to stop growing or even die.</p><p>Normal cells only start replicating their DNA when there are substances known as growth factors in the environment. Without growth factors cells remain in the first phase of the cell cycle, known as G1. Most cancer cells, however, lack this ‘G1 checkpoint’ and enter the cell cycle even when growth factors are absent. This leads to DNA replication problems and damage that should cause the cells to die. Yet a characteristic of cancer cells is that they overcome these problems to grow and divide uncontrollably.</p><p>Cancer cells also often lack a protein called p53. Previous studies demonstrated that the lack of p53 helps tumor cells to survive by maintaining cell growth and reducing the likelihood of cell death. By growing cells in culture without growth factors, Benedict, van Harn et al. now show that p53 also helps cells that lack the G1 checkpoint to continue dividing.</p><p>In the experiments, cells that lacked the G1 checkpoint but still contained the p53 protein suffered from DNA replication problems and DNA damage, and subsequently died. Deleting p53 from these cells stimulated DNA replication, stopped cells from dying and helped to prevent the DNA from getting damaged. Cells could thus grow and proliferate under unfavorable conditions. Benedict, van Harn et al. also deleted p53 in tumor cells growing under the skin of mice and observed less DNA damage in these cells than in tumor cells that still have p53.</p><p>Despite reduced levels of DNA damage, the cells still had severe DNA replication problems. It is possible that these cells rely on mechanisms that allow just enough DNA replication to occur to support their proliferation. Cancer cells may therefore be highly vulnerable to drugs that interfere with these mechanisms, since they are already using them as a last resort. Future experiments will be needed to identify these mechanisms.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>replication stress</kwd><kwd>DNA double strand breaks</kwd><kwd>p53</kwd><kwd>origin firing</kwd><kwd>G1/S phase checkpoint</kwd><kwd>retinoblastoma</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004622</institution-id><institution>KWF Kankerbestrijding</institution></institution-wrap></funding-source><award-id>2007-3790</award-id><principal-award-recipient><name><surname>van Harn</surname><given-names>Tanja</given-names></name><name><surname>Kucukosmanoglu</surname><given-names>Asli</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004410</institution-id><institution>European Molecular Biology Organization</institution></institution-wrap></funding-source><award-id>194-2011</award-id><principal-award-recipient><name><surname>van Harn</surname><given-names>Tanja</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004622</institution-id><institution>KWF Kankerbestrijding</institution></institution-wrap></funding-source><award-id>2014-6702</award-id><principal-award-recipient><name><surname>Benedict</surname><given-names>Bente</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>During tumorigenesis loss of p53 not only abrogates cell cycle arrest and apoptosis, but also suppresses the induction of replication-stress-induced DNA double-stranded breaks.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>To prevent cells become cancerous, different cell-cycle checkpoints can be activated to halt cell cycle progression. The G1/S checkpoint is responsible for controlling S phase entry and key effectors of this checkpoint are the retinoblastoma (Rb) proteins pRB, p107 and p130. Anti-proliferative conditions, such as lack of growth factors, suppress the activity of the D-type cyclin-dependent kinases (CDKs) CDK4 and CDK6. This results in hypo-phosphorylation of the Rb proteins, which can then bind E2F transcription factors thereby inhibiting the transcription of E2F target genes required for S-phase entry (<xref ref-type="bibr" rid="bib6">Bertoli et al., 2013</xref>; <xref ref-type="bibr" rid="bib11">Burkhart and Sage, 2008</xref>). In a majority of human tumors, the G1/S checkpoint is lost, for example by loss of pRB or the CDK inhibitor p16<sup>INK4A</sup>, or by overexpression of Cyclin D1 (<xref ref-type="bibr" rid="bib27">Ho and Dowdy, 2002</xref>; <xref ref-type="bibr" rid="bib63">Weinberg, 2007</xref>) and insensitivity to antigrowth signals is an hallmark of tumor cells (<xref ref-type="bibr" rid="bib25">Hanahan and Weinberg, 2000</xref>). Cells lacking the G1/S phase checkpoint can start synthesizing DNA under non-permissive conditions which may lead to DNA damage.</p><p>To deal with DNA damage, cells have evolved another cell cycle checkpoint that is part of the DNA-damage response (DDR) (<xref ref-type="bibr" rid="bib30">Jackson and Bartek, 2009</xref>). Activation of the DNA damage checkpoint triggers cellular senescence or cell death, thereby providing an intrinsic biological barrier against tumor progression (<xref ref-type="bibr" rid="bib3">Bartkova et al., 2006</xref>; <xref ref-type="bibr" rid="bib23">Gorgoulis et al., 2005</xref>). It is often rationalized that inactivation of <italic>Trp53</italic>, a central player in the DDR and the most frequently mutated gene in human cancer (<xref ref-type="bibr" rid="bib43">Olivier et al., 2010</xref>), promotes tumorigenesis by counteracting apoptosis and senescence induced by a defective G1/S checkpoint (<xref ref-type="bibr" rid="bib58">Sherr and McCormick, 2002</xref>; <xref ref-type="bibr" rid="bib52">Reinhardt and Schumacher, 2012</xref>; <xref ref-type="bibr" rid="bib49">Polager and Ginsberg, 2009</xref>; <xref ref-type="bibr" rid="bib10">Bunz et al., 1998</xref>; <xref ref-type="bibr" rid="bib9">Bieging et al., 2014</xref>). However, here we present an unanticipated effect of p53 loss in cells that lack G1/S control.</p><p>To study the consequences of G1/S checkpoint loss in a well-defined system, we used primary mouse embryonic fibroblasts (MEFs) in which the three retinoblastoma (Rb) genes were inactivated. Previously, we and others demonstrated that these so-called triple knockout (TKO) MEFs can enter S phase without mitogenic signaling (<xref ref-type="bibr" rid="bib13">Dannenberg et al., 2000</xref>; <xref ref-type="bibr" rid="bib54">Sage et al., 2000</xref>). However, proliferation of TKO MEFs was still mitogen dependent: without mitogens, most cells became apoptotic whereas surviving cells arrested in a G2-like state. Suppression of apoptosis by ectopic expression of Bcl2 (TKO-Bcl2 MEFs) revealed that G2 arrest resulted from induction of p27<sup>Kip1</sup> and p21<sup>Cip1</sup> that inhibit Cyclin A- and B1-dependent kinase activity (<xref ref-type="bibr" rid="bib19">Foijer et al., 2005</xref>). Induction of p21<sup>Cip1</sup> upon mitogen deprivation may be indicative for DNA damage (<xref ref-type="bibr" rid="bib33">Karimian et al., 2016</xref>). Intriguingly, we previously showed that RNAi-mediated suppression of p53 and thereby reduction of p21<sup>Cip1</sup> levels revitalized CDK activity and supported mitogen-independent proliferation of Rb-protein-deficient cells (<xref ref-type="bibr" rid="bib19">Foijer et al., 2005</xref>). In the present study, we provide mechanistic insight into the relief of proliferative arrest in mitogen-deprived TKO cells by p53 loss. We show that the DNA DSBs observed in mouse and human cells lacking G1/S phase control are caused by replication stress reflected by decreased replication speed and reduced origin firing. Inactivation of <italic>p53</italic> allowed for mitogen-independent proliferation, not only by suppressing apoptosis but also by restoring the levels of origin firing and reducing DSB formation. Similarly, in an <italic>in vivo</italic> model and in Rb-protein-deficient human cells, DNA breakage was reduced by loss of <italic>p53</italic>.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Loss of p53/p21<sup>Cip1</sup> allows mitogen-independent proliferation of cells lacking the G1/S checkpoint</title><p>Consistent with our previous observations (<xref ref-type="bibr" rid="bib19">Foijer et al., 2005</xref>), mouse embryonic fibroblast (MEFs) lacking the three retinoblastoma proteins and overexpressing the anti-apoptotic gene <italic>Bcl2</italic> (TKO-Bcl2 MEFs) ceased proliferation upon mitogen deprivation (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, black line) and arrested in a G2-like state (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, upper panel). We also reported that proliferation was rescued by RNAi-mediated knockdown of <italic>Trp53</italic>, the gene that encodes the p53 protein (TKO-p53RNAi MEFs) (<xref ref-type="bibr" rid="bib19">Foijer et al., 2005</xref>). However, in recent experiments, proliferation of mitogen-starved TKO-p53RNAi MEFs appeared transient and was followed by severe cell loss (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, green line), possibly as a result of residual p53 activity (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). We therefore exploited CRISPR/Cas9 technology to create full <italic>Trp53</italic> knockout (KO) TKO MEFs (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Disruption of <italic>p53</italic> clearly rescued proliferation of mitogen-starved TKO MEFs (TKO-p53KO) and this effect was even greater in TKO MEFs expressing Bcl2 (TKO-Bcl2-p53KO), which reached 100% confluency (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, blue and red lines). The improved proliferative capacity was accompanied by reduced apoptosis (<xref ref-type="fig" rid="fig1">Figure 1B</xref>) and the absence of G2 arrest (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, lower panel, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). Mitogen-deprived TKO-Bcl2-p53KO cells maintained a cell cycle profile similar to cells cultured in the presence of mitogens (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, lower panel) and, unlike TKO-Bcl2 cells, continued to incorporate high levels of nucleotides (<xref ref-type="fig" rid="fig1">Figure 1D</xref>).</p><fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.37868.003</object-id><label>Figure 1.</label><caption><title>Loss of p53/p21<sup>Cip1</sup> promotes proliferation of mitogen-deprived MEFs lacking G1/S phase checkpoint.</title><p>(<bold>A</bold>) IncuCyte growth curves of TKO-Bcl2 (black), TKO-p53RNAi (green), TKO-p53KO (blue) and TKO-Bcl2-p53KO (red) MEFs in the absence of 10% FCS. (<bold>B</bold>) Apoptosis levels of TKO-Bcl2 (black), TKO-p53RNAi (green), TKO-p53KO (blue) and TKO-Bcl2-p53KO (red) MEFs in the absence of 10% FCS. Apoptosis was measured by fluorescent signal upon caspase three cleavage and normalized to cell confluency. (<bold>C</bold>) Cell cycle distribution based on propidium iodide content of TKO-Bcl2 MEFs (upper panel) and TKO-Bcl2-p53KO MEFs (lower panel) in the absence of 10% FCS for the indicated days. (<bold>D</bold>) BrdU flow cytometry analysis of the cell cycle distribution of TKO-Bcl2 and TKO-Bcl2-p53KO MEFs in the absence of 10% FCS for the indicated days. Percentage of BrdU-labeled cells is indicated. (<bold>E</bold>) IncuCyte growth curves of TKO-Bcl2 (black), TKO-Bcl2-p53KO (red) and TKO-Bcl2-p21KO (blue) MEFs in the absence of 10% FCS. Experiments in A, B and E were performed in triplicate. Error bars show standard deviation (sd).</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-37868-fig1-v2"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.37868.004</object-id><label>Figure 1—figure supplement 1.</label><caption><title>Reduced G2 arrest in mitogen-starved TKO-p53RNAi and TKO-p53KO MEFs.</title><p>(<bold>A</bold>) p21<sup>Cip1</sup> and p53 protein levels in TKO-Bcl2, TKO-p53RNAi, p53KO, TKO-p53KO andTKO-Bcl2-p53KO MEFs. Anti-CDK4 was used as a loading control. (<bold>B</bold>) Cell cycle distribution based on propidium iodide content of TKO-p53RNAi MEFs (left panel) and TKO-p53KO MEFs (right panel) in the absence of 10% FCS for the indicated days. (<bold>C</bold>) Using a CRISPR vector, <italic>Cdkn1a</italic> was disrupted in TKO-Bcl2 cells. p21<sup>Cip1</sup> protein levels were measured after irradiation with 10 Gy. One of the clones expressed elongated p21<sup>Cip1</sup> protein. The clone with absent p21<sup>Cip1</sup> staining (TKO-Bcl2-p21KO) was used in further experiments. Anti-actin was used as a loading control.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-37868-fig1-figsupp1-v2"/></fig></fig-group><p>Not only loss of <italic>p53</italic>, but also disruption of its downstream target <italic>Cdkn1a</italic>, the gene that encodes the p21<sup>Cip1</sup> protein (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>), rescued proliferation of mitogen-deprived TKO-Bcl2 cells (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). Apparently, the induction of p21<sup>Cip1</sup>, which we previously found to inhibit Cyclin A- and B1-dependent kinases (<xref ref-type="bibr" rid="bib19">Foijer et al., 2005</xref>), was critical for G2-like arrest of mitogen-deprived TKO cells. The p53/p21<sup>Cip1</sup> axis is part of the DNA damage response (DDR) and its activation is consistent with the high levels of DNA double-strand breaks (DSBs) that accumulated in arrested TKO-Bcl2 cells (<xref ref-type="bibr" rid="bib61">van Harn et al., 2010</xref>). To understand how disruption of p53/p21<sup>Cip1</sup> rescued proliferation, we investigated the mechanism of DSB formation.</p></sec><sec id="s2-2"><title>Mitogen deprivation causes S-phase delay</title><p>We studied cell cycle progression of individual cells using the Fucci system, in which fluorescent proteins fused to the degradation motifs of Cdt1 and Geminin mark G1 and S/G2 cells, respectively (<xref ref-type="bibr" rid="bib55">Sakaue-Sawano et al., 2008</xref>). In the presence of mitogens, TKO-Bcl2 and TKO-Bcl2-p53KO MEFs proliferated with a cell-cycle duration of 10 to 15 hr (<xref ref-type="fig" rid="fig2">Figure 2A,B</xref>, left). In the absence of mitogens, TKO-Bcl2 MEFs arrested in S/G2 phase, either immediately or after one cell cycle (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, right). In contrast, mitogen-deprived TKO-Bcl2-p53KO MEFs could be followed for two or three cell divisions (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, right), although G1 and S/G2 phase durations were increased, together encompassing 15 to 30 hr. These tracking experiments confirm that TKO-Bcl2-p53KO MEFs can proliferate in the absence of mitogens albeit at slower pace.</p><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.37868.005</object-id><label>Figure 2.</label><caption><title>Loss of p53 rescues G2 arrest in mitogen-deprived TKO-Bcl2 MEFs.</title><p>Timing of cell cycle phases in (<bold>A</bold>) TKO-Bcl2 MEFs and (<bold>B</bold>) TKO-Bcl2-p53KO MEFs expressing mKO-hCdt1 and mAG-hGem and cultured in the presence (left panels) or absence (right panels) of 10% FCS. The period a cell only expressed mKO-hCdt1 (G1 phase) is marked red, only expressed mAG-hGem (S/G2/M phase) is marked green, expressed both mKO-hCdt1 and mAG-hGem (early S phase) is marked yellow. During mitosis both markers are absent (white).The y-axes represent individual cells.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-37868-fig2-v2"/></fig></sec><sec id="s2-3"><title><italic>p53/p21<sup>Cip1</sup></italic> knockout suppresses DSBs formation</title><p>Cell cycle delay may be caused by DSBs that accumulate in mitogen-deprived TKO-Bcl2 MEFs (<xref ref-type="bibr" rid="bib61">van Harn et al., 2010</xref>). This level was comparable to irradiation with 20 Gy, which is expected to severely impair mitosis resulting in cell death (<xref ref-type="bibr" rid="bib67">Zachos et al., 2003</xref>). Nonetheless, TKO-Bcl2-p53KO and TKO-Bcl2-p21KO MEFs were able to proliferate mitogen-independently. We therefore investigated whether <italic>Trp53</italic> or <italic>Cdkn1a</italic> inactivation affected DSB formation as a consequence of mitogen deprivation by performing neutral comet assays (<xref ref-type="bibr" rid="bib42">Olive and Banáth, 2006</xref>). Mitogen restriction of TKO-Bcl2 MEFs caused a clear increase in tail moment, an indicator of the level of DSBs (<xref ref-type="fig" rid="fig3">Figure 3A,B</xref>). In contrast, the tail moments in TKO-Bcl2-p53KO and TKO-Bcl2-p21KO MEFs were not significantly increased by mitogen depletion (<xref ref-type="fig" rid="fig3">Figure 3B</xref>) although the basal levels of DSBs (<italic>i.e.</italic>, in the presence of mitogens) were somewhat higher compared to TKO-Bcl2 cells. Possibly, MEFs accumulated some DNA damage under optimal culture conditions that was tolerated or not adequately repaired in the absence of p53/p21<sup>Cip1</sup> activity (<xref ref-type="bibr" rid="bib38">Levine and Oren, 2009</xref>; <xref ref-type="bibr" rid="bib64">Williams and Schumacher, 2016</xref>). Nevertheless, the critical observation here is that the induction of DNA breakage <italic>due to mitogen deprivation</italic> was suppressed in the absence of p53/p21<sup>Cip1</sup>.</p><fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.37868.006</object-id><label>Figure 3.</label><caption><title>Loss of p53 reduces DNA double-stranded breaks.</title><p>(<bold>A</bold>) Representative comets of nuclei of TKO-Bcl2, TKO-Bcl2-p53KO MEFs and TKO-Bcl2-p21KO MEFs stained with propidium iodide in the presence or absence of 10% FCS (7 days). (<bold>B</bold>) Tail moments obtained from TKO-Bcl2, TKO-Bcl2-p53KO and TKO-Bcl2-p21KO MEFs cultured in the presence or absence of 10% FCS (7 days). (<bold>C</bold>) Tail moments obtained from TKO-Bcl2 and TKO-Bcl2-p53KO MEFs cultured in the presence or absence of 10% FCS (2 days) and in the presence of nocodazole. (<bold>D</bold>) Tail moments obtained from TKO-Bcl2 and TKO-Bcl2-p53KO MEFs immediately and 30 min after 1 hr treatment with 2 mM HU. In B, C and D, box plots represent interquartile ranges, horizontal bars denote the median and points indicate outliers. For each condition, more than 50 cells were analyzed using the CASP software. Significance is indicated (1-way Anova nonparametric Kruskal-Wallis test).</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-37868-fig3-v2"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.37868.007</object-id><label>Figure 3—figure supplement 1.</label><caption><title>Nocodazole-induced cell cycle arrest to prevent G1 entry.</title><p>Propidium iodide staining cell cycle analysis of TKO-Bcl2 and TKO-Bcl2-p53KO MEFs cultured in the presence of 10% FCS (left panels) and in the absence of 10% FCS and in the presence of 250 ng/ml nocodazole (right panels).</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-37868-fig3-figsupp1-v2"/></fig></fig-group><p>It is known that p53 modulates different DNA repair pathways (<xref ref-type="bibr" rid="bib9">Bieging et al., 2014</xref>; <xref ref-type="bibr" rid="bib64">Williams and Schumacher, 2016</xref>). Could the level of DSBs in mitogen-deprived p53KO MEFs be reduced by passage through M phase and subsequent repair in G1? To examine this possibility, we blocked cell cycle progression towards G1 by culturing cells in medium without mitogens, but containing nocodazole (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). This allowed us to measure the level of DSBs in TKO-Bcl2 and TKO-Bcl2-p53KO cells in comparable cell cycle phases, between S and M phase. In the presence of nocodazole, the same results were obtained: mitogen-deprived TKO-Bcl2 MEFs showed the expected increase in tail moment, while the tail moments of TKO-Bcl2-p53KO MEFs were still not increased (<xref ref-type="fig" rid="fig3">Figure 3C</xref>).</p><p>To directly investigate whether p53 status affected repair of replication-stress-induced DSBs, we treated <italic>mitogen-stimulated</italic> TKO-Bcl2 MEFs with 2 mM hydroxyurea (HU) for 1 hr in order to induce and alleviate replication stress instantaneously. HU depletes the cells of nucleotides, which results in stalling and collapsing of replication forks and hence DNA breakage (<xref ref-type="bibr" rid="bib8">Bianchi et al., 1986</xref>; <xref ref-type="bibr" rid="bib36">Koç et al., 2004</xref>). When comparing cells harvested immediately after HU treatment and cells harvested 30 min after HU treatment, we observed an equally strong decrease in tail moment in TKO-Bcl2 and in TKO-Bcl2-p53KO MEFs (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). This indicates that the repair of DSBs induced by HU treatment was independent of p53 status. Assuming that repair of replication-stress-induced DSBs under mitogen-deprived conditions follows similar rules, these results suggest that reduced levels of DSBs in mitogen-deprived TKO-Bcl2-p53KO cells resulted from suppressed formation rather than increased repair of DSBs.</p></sec><sec id="s2-4"><title>Mitogen-deprived TKO-Bcl2 MEFs suffer from replication stress</title><p>To study the mechanism of DNA breakage, we assessed the quality of DNA replication in mitogen-deprived TKO-Bcl2 MEFs by looking at co-localization of the thymidine analogue chloro-deoxyuridine (CldU, marking DNA replication) and γ-H2AX (marking DNA damage). While the number of cells containing CldU foci gradually decreased in mitogen-starved TKO-Bcl2 MEFs, virtually all CldU foci that were still present after 4 and 7 days co-localized with γ-H2AX foci (<xref ref-type="fig" rid="fig4">Figure 4A,B</xref>). Furthermore, the gradual increase of phosphorylated Chk1 (pChk1), a target of ataxia telangiectasia related (ATR), is indicative for accumulation of single-stranded DNA (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Taken together, these results are indicative for perturbed replication in mitogen-deprived TKO-Bcl2 MEFs.</p><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.37868.008</object-id><label>Figure 4.</label><caption><title>Mitogen-deprived TKO-Bcl2 MEFs suffer from replication stress.</title><p>(<bold>A</bold>) CldU and γ-H2AX foci in TKO-Bcl2 MEFs cultured in the absence of 10% FCS for 4 days. DNA was labeled with To-Pro3. In the merged picture, DNA is blue, γ-H2AX is green, CldU is red and co-localization of γ-H2AX and CldU is seen as yellow foci. (<bold>B</bold>) Quantification of CldU positive TKO-Bcl2 MEFs cultured in the absence of 10% FCS for the indicated days that contained five or more superimposed γ-H2AX and CldU foci. At least 100 cells were counted per condition. Standard deviation (error bars) between at least five different microscopic slides are shown. Significant differences between average values are indicated with an asterisk (Student’s t-test, p&lt;0.01). (<bold>C</bold>) pChk1 (Chk1 phosphorylated on Ser317, upper panel) and Chk1 protein levels (middle panel) in TKO-Bcl2 MEFs cultured in the presence or absence of 10% FCS for the indicated days. Anti-CDK4 was used as loading control (lower panel).</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-37868-fig4-v2"/></fig><p>We next visualized the progression of individual replication forks using a DNA fiber assay (<xref ref-type="bibr" rid="bib60">Tuduri et al., 2010</xref>). Sequential pulse-labeling of newly synthesized DNA strands with the thymidine analogs CldU (red tracks) and iodo-deoxyuridine (IdU, green tracks) identifies ongoing replication forks and new origin firing (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). The length of double-labelled tracks in TKO-Bcl2 MEFs cultured with FCS indicated an average fork speed of 1.66 kb/min (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). In the absence of <italic>p53</italic> the average fork speed was somewhat lower, 1.37 kb/min, consistent with a previous study (<xref ref-type="bibr" rid="bib35">Klusmann et al., 2016</xref>). Mitogen deprivation caused a progressive decline in replication speed, somewhat unexpectedly not only in arresting TKO-Bcl2 MEFs but also in proliferating TKO-Bcl2-p53KO MEFs (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Prolonged S-phase and decelerated DNA synthesis indicate that mitogen-deprived TKO-Bcl2-p53KO MEFs were able to proliferate despite sustained replication stress.</p><fig-group><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.37868.009</object-id><label>Figure 5.</label><caption><title>Loss of p53 restores the level of origin firing.</title><p>(<bold>A</bold>) Schematic representation of replication tracks generated after pulse labeling with CldU (red) and IdU (green). Ongoing forks were used to determine fork speeds (kb/min); 1<sup>st</sup> label and 2<sup>nd</sup> label origins are origins of replication initiated during the labelling period with CldU and IdU, respectively (upper panel). Representative images of DNA fibers of TKO-Bcl2 MEFs with and without 10% FCS (lower panel). (<bold>B</bold>) Replication fork speeds in TKO-Bcl2 and TKO-Bcl2-p53KO MEFs cultured in the presence or absence of 10% FCS for 1–7 days. Box plots represent interquartile ranges, horizontal bars denote the median, whiskers indicate 5–95 percentile and points are outliers. At least 350 track lengths of ongoing forks were measured (from three independent experiments) with ImageJ. Significant differences between median values are indicated with an asterisk (nonparametric Kruskal-Wallis test, p&lt;0.05). (<bold>C</bold>) Quantification of origin firing in TKO-Bcl2, TKO-Bcl2-p53KO and TKO-Bcl2-p21KO MEFs cultured in the presence or absence of 10% FCS for 1–5 days. 1<sup>st</sup> label and 2<sup>nd</sup> label origins are shown as percentage of all labeled tracks (from three independent experiments). Significant differences between average values are indicated with an asterisk (p&lt;0.05, Student’s t-test).</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-37868-fig5-v2"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.37868.010</object-id><label>Figure 5—figure supplement 1.</label><caption><title>Nucleotide deficiency is not causal to G2 arrest.</title><p>(<bold>A</bold>) Transcript levels of <italic>Ppat</italic>, <italic>Impdh1</italic>, <italic>Impdh2</italic> and <italic>Paics</italic> (corrected for <italic>Hprt</italic> transcript levels) in TKO-Bcl2 MEFs cultured in the presence or absence of 10% FCS for the indicated days. The expression in the presence of 10% FCS is set as 100%. Standard deviation (bars) from two independent experiments is shown. (<bold>B</bold>) Transcript level of <italic>Ppat</italic> (corrected for <italic>Hprt</italic> transcript level) in TKO-Bcl2 MEFs 2 days after transduction with shRNAs against <italic>Ppat</italic> (#1 and #2) or non-targeting shRNA (EV, set as 100%). Standard deviation (bars) of three independent experiments is shown. (<bold>C</bold>) Replication fork speeds in TKO-Bcl2 MEFs 2 days after transduction with shRNAs against <italic>Ppat</italic> (#1 and #2) or non-targeting shRNA (EV). (<bold>D</bold>) Replication fork speeds in TKO-Bcl2 MEFs cultured in the presence or absence of 10% FCS for 1 day with or without the exogenous supply of nucleosides. For C and D, box plots represent interquartile ranges, horizontal bars denote the median, whiskers indicate 5–95 percentile and points are outliers. At least 100 track lengths of ongoing forks were measured. Average values marked with asterisk are significantly different (nonparametric Kruskal-Wallis test, p&lt;0.05). (<bold>E</bold>) Cell cycle distribution of TKO-Bcl2 MEFs cultured in the presence or absence of 10% FCS for the indicated days with or without daily exogenous supply of nucleosides. (<bold>F</bold>) pChk1 (Ser317), Chk1, p21<sup>Cip1</sup> and p27<sup>Kip1</sup> protein levels in TKO-Bcl2 MEFs cultured in the presence or absence of 10% FCS for the indicated days in the presence or absence of nucleosides. Anti-CDK4 was used as loading control.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-37868-fig5-figsupp1-v2"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.37868.011</object-id><label>Figure 5—figure supplement 2.</label><caption><title>DNA replication stress induced by 0.3 and 2 mM Hydroxyurea.</title><p>(<bold>A</bold>) Tail moments obtained from TKO-Bcl2 and TKO-Bcl2-p53KO cultured in the absence or presence of 0.3 or 2 mM HU for 1 hr. Box plots represent interquartile ranges, horizontal bars denote the median and points are outliers. For each condition, more than 50 cells were analyzed using the CASP software. Significance is indicated (nonparametric Mann Whitney test). (<bold>B</bold>) Quantification of origin firing of TKO-Bcl2 and TKO-Bcl2-p53KO MEFs after 1 hr treatment with 0.3 or 2 mM HU. Origins (green only) are shown as percentage of stalled (red only) and restarted tracks (red-green or green-red-green). The experiment was performed in duplicate. Error bars show standard deviation.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-37868-fig5-figsupp2-v2"/></fig></fig-group></sec><sec id="s2-5"><title>Nucleotide deficiency contributes to perturbed DNA replication</title><p>Disruption of the nucleotide pool can contribute to replication stress (<xref ref-type="bibr" rid="bib7">Bester et al., 2011</xref>; <xref ref-type="bibr" rid="bib50">Poli et al., 2012</xref>) and may therefore be the underlying cause of reduced replication speed, DSB formation and G2-like arrest in mitogen-deprived TKO-Bcl2 MEFs. Mitogen deprivation is a strong anti-proliferative signal that may inhibit MYC transcription factors and therefore repress genes involved in nucleotide synthesis (<xref ref-type="bibr" rid="bib22">Gassmann et al., 1999</xref>; <xref ref-type="bibr" rid="bib44">Perna et al., 2012</xref>). Indeed, we found that mitogen-deprivation of TKO-Bcl2 cells reduced transcript levels of phosphoribosyl pyrophosphate amidotransferase (<italic>Ppat</italic>) and inosine monophosphate dehydrogenase 1 and 2 (<italic>Impdh1</italic> and <italic>Impdh2</italic>), genes involved in purine metabolism, 2-fold (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). Reduced levels of nucleotide synthesis enzymes could impair DNA replication by disturbing the balance in the dNTP pool. Indeed, RNAi-mediated suppression of <italic>Ppat</italic> expression (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>) reduced the replication speed in mitogen-stimulated TKO-Bcl2 MEFs from 1.25 kb/min to 0.84 (shRNA #1) and 0.86 (shRNA #2) kb/min (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>).</p><p>Conversely, replication speed in mitogen-deprived TKO-Bcl2 MEFs could be partially rescued by the exogenous supply of nucleosides. Similar to previous experiments, one day of mitogen deprivation decreased the average fork speed by ±30%, in this experiment from 0.94 kb/min to 0.65 kb/min. In contrast, when cells were supplemented with nucleosides, reduction of replication speed was less pronounced (from 1.03 kb/min to 0.83 kb/min) (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>). However, daily nucleosides supplementation did not alleviate the proliferation defect of mitogen-deprived TKO-Bcl2 MEFs: G2 accumulation was hardly affected (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1E</xref>) and also Chk1 phosphorylation and p21<sup>Cip1</sup> induction were not reduced (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1F</xref>). As we observed that mitogen-independent proliferation upon <italic>p53</italic> loss did not require restoration of replication speed (<xref ref-type="fig" rid="fig5">Figure 5B</xref>), this indicates that rather than decelerated DNA replication another factor was causal to G2 arrest upon mitogen deprivation.</p></sec><sec id="s2-6"><title>Reduced DNA breakage by p53 knockout is associated with increased origin firing</title><p>Previously, we showed that inhibition of CDK activity by p27<sup>Kip1</sup> and p21<sup>Cip1</sup> was critical for arrest of mitogen-deprived TKO-Bcl2 MEFs (<xref ref-type="bibr" rid="bib19">Foijer et al., 2005</xref>). Since CDK activity is required to activate origins of replication (<xref ref-type="bibr" rid="bib20">Fragkos et al., 2015</xref>; <xref ref-type="bibr" rid="bib39">Méndez and Stillman, 2003</xref>), origin firing may be perturbed in mitogen-deprived TKO-Bcl2 MEFs. Indeed, among CldU/IdU-labelled DNA fibers from mitogen-deprived TKO-Bcl2 MEFs, staining patterns indicative for new origin firing were significantly reduced (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). In contrast, in TKO-Bcl2-p53KO MEFs, origin firing was <italic>not</italic> disturbed during the first days of mitogen deprivation and maintained levels similar as in mitogen-stimulated cells (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Only after 5 days of mitogen deprivation, origin firing was reduced, which may be related to the state of confluency that was reached by that time (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Similar to TKO-Bcl2-p53KO MEFs, also TKO-Bcl2-p21KO MEFs maintained normal origin firing during the first days of mitogen deprivation (<xref ref-type="fig" rid="fig5">Figure 5C</xref>).</p><p>The increased level of origin firing upon loss of p53/p21<sup>Cip1</sup> contrasts to a recent publication by Roy et al. who identified a transcription-independent function of p53 in balancing replication fork homeostasis and, in contrast to our findings, observed a decrease in the level of origin firing upon loss of p53 (<xref ref-type="bibr" rid="bib5">Beroukhim et al., 2010</xref>). An explanation for this seeming discrepancy may be found in comparing the different replication stress conditions. Roy et al. studied the role of p53 in conditions with a low dose of HU that did not induce DSBs. In contrast, by serum starvation we induced severe replication stress as observed by the drastic decrease of replication fork progression and induction of DNA breaks (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). We therefore compared the consequences of low <italic>versus</italic> high doses of HU. A low dose of HU (300 µM) did not induce DNA DSBs whereas a high dose of HU (2 mM) did (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2A</xref>). Consistent with Roy et al., loss of p53 reduced the level of origin firing upon treatment with 300 µM HU. However, loss of p53 did not change the level of origin firing after treatment with the high dose of HU (2 mM) (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2B</xref>).</p><p>Collectively, our results suggest that under conditions of severe replication stress, restoration of the level of origin firing upon p53 loss prevents DNA breakage, allowing mitogen-independent proliferation of TKO-Bcl2-p53KO MEFs.</p></sec><sec id="s2-7"><title>Also in human cells inactivation of p53 is associated with reduced DNA DSBs</title><p>To investigate whether p53 affects DNA breakage under replication stress conditions in human cells, we used the human retinal pigment epithelial cell line RPE-1. The G1/S phase checkpoint was perturbed either by inactivating all three retinoblastoma genes, <italic>RB</italic>, <italic>RBL1</italic> and <italic>RBL2</italic> (TKO; <xref ref-type="fig" rid="fig6">Figure 6A</xref>) or by overexpressing a non-degradable form of human Cyclin D1 (CyclinD1; <xref ref-type="fig" rid="fig6">Figure 6B</xref>). Overexpression of Cyclin D1 is biologically relevant since the gene encoding Cyclin D1 represents the second most frequently amplified locus in the human cancer genome (<xref ref-type="bibr" rid="bib5">Beroukhim et al., 2010</xref>). In addition, in many human tumors overexpression of D type cyclins takes place in the absence of detectable genomic alterations (<xref ref-type="bibr" rid="bib28">Hosokawa and Arnold, 1998</xref>). In the presence of mitogens, TKO and CyclinD1 RPE-1 cells proliferated faster than wild type RPE-1s (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). 24 hr after mitogen-deprivation, wild type RPE-1s arrested in the G1 phase of the cell cycle (<xref ref-type="fig" rid="fig6">Figure 6C</xref>), whereas both, TKO and CyclinD1 cultures maintained a normal cell cycle profile up to 72 hr (<xref ref-type="fig" rid="fig6">Figure 6D and E</xref>, respectively). Upon prolonged mitogen starvation for more than 4 days, TKO and CyclinD1 cells started to die (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>). Cell death could not be avoided by overexpression of Bcl2 (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C, D and E</xref>) nor by additional inactivation of <italic>TP53</italic> (<xref ref-type="fig" rid="fig6">Figure 6F,G</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1F</xref>). Apparently, RPE-1 cells lacking the G1/S phase checkpoint were very sensitive to apoptosis in the absence of mitogenic stimulation, which could not easily be suppressed. Nonetheless, we could follow the behavior of these cells during the first days of mitogen deprivation. Similar to TKO-Bcl2 MEFs, p53-proficient TKO-Bcl2 RPE-1s showed induction of DNA DSBs after one day of mitogen starvation. In contrast, no DSB induction was seen in TKO-Bcl2-p53KO RPE-1s (<xref ref-type="fig" rid="fig6">Figure 6H</xref>). Similarly, mitogen starvation hardly induced DSBs in CyclinD1-Bcl2-p53KO RPE-1s compared to CyclinD1-Bcl2 RPE-1s (<xref ref-type="fig" rid="fig6">Figure 6I</xref>). Mitogen-deprived TKO-Bcl2 and CyclinD1-Bcl2 RPE-1s showed a decrease in the level origin firing (<xref ref-type="fig" rid="fig6">Figure 6J,K</xref>). In contrast, TKO-Bcl2-p53KO and CyclinD1-Bcl2-p53KO RPE1-s maintained normal levels of origin firing after mitogen deprivation (<xref ref-type="fig" rid="fig6">Figure 6J,K</xref>), although there is no difference in replication fork speed upon mitogen-deprivation (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1G and F</xref>).</p><fig-group><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.37868.012</object-id><label>Figure 6.</label><caption><title>Loss of p53 reduces DNA double-strand breaks in human cells.</title><p>(<bold>A</bold>) Rb, Rbl1 and Rbl2 protein levels in wt and TKO RPE-1s. Anti-actin was used as a loading control. (<bold>B</bold>) Cyclin D1 protein levels in wt and CyclinD1 RPE-1s. Anti-actin was used as a loading control. (<bold>C, D, E</bold>) Cell cycle distribution based on propidium iodide content of wt (<bold>C</bold>), TKO (<bold>D</bold>) and CyclinD1 (<bold>E</bold>) RPE-1s in the absence of 10% FCS for the indicated hours. (<bold>F</bold>) p53 and p21<sup>Cip1</sup> protein levels in wt, Bcl2-p53KO and TKO-Bcl2-p53KO RPE-1s. Anti-actin was used as a loading control. (<bold>G</bold>) p53 and p21<sup>Cip1</sup> protein levels in wt, CyclinD1-Bcl2 and CyclinD1-Bcl2-p53KO RPE-1s. Anti-actin was used as a loading control. (<bold>H, I</bold>) Tail moments obtained from TKO-Bcl2, TKO-Bcl2-p53KO (<bold>H</bold>) and CyclinD1-Bcl2 and CyclinD1-Bcl2-p53KO (<bold>I</bold>) RPE1-s cultured in the presence or absence of 10% FCS (1 day). Box plots represent interquartile ranges, horizontal bars denote the median and points are outliers. For each condition, more than 50 cells were analyzed using the CASP software. Significance is indicated (1-way Anova nonparametric Kruskal-Wallis test). (<bold>J, K</bold>) Quantification of origin firing in TKO-Bcl2, TKO-Bcl2-p53KO (<bold>J</bold>) and CyclinD1-Bcl2 and CyclinD1-Bcl2-p53KO (<bold>K</bold>) RPE1-s cultured in the presence or absence of 10% FCS for 1 day. 1<sup>st</sup> label and 2<sup>nd</sup> label origins are shown as percentage of all labelled tracks (from two independent experiments). Significant differences between average values are indicated (Student’s t-test).</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-37868-fig6-v2"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.37868.013</object-id><label>Figure 6—figure supplement 1.</label><caption><title>Response of RPE1 cells to mitogen starvation</title><p>(<bold>A</bold>) Incucyte growth curves of wt (black), TKO (blue) en CyclinD1 RPE1-s (red) in mitogen proficient conditions. (<bold>B</bold>) Representative images of wt, TKO and CyclinD1 RPE-s in the presence of FCS and after 4 days of FCS deprivation. (<bold>C</bold>) Bcl2 protein levels of wt, TKO, wt-Bcl2 and TKO-Bcl2 RPE1-s. Anti-actin was used as loading control. (<bold>D</bold>) Bcl2 protein levels of CyclinD1, CyclinD1-Bcl2 and CyclinD1-Bcl2-p53KO RPE1-s. Anti-actin was used as loading control. (<bold>E</bold>) Representative images TKO-Bcl2 and CyclinD1-Bcl2 RPE-s in the presence of 10% FCS and after 4 days of 10% FCS deprivation. (<bold>F</bold>) Representative images of TKO-Bcl2-p53KO and CyclinD1-Bcl2-p53KO RPE1-s in the presence of FCS and after 4 days of 10% FCS deprivation.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-37868-fig6-figsupp1-v2"/></fig></fig-group><p>These results show that also in human cells inactivation of p53 in G1/S phase checkpoint defective cells reduced the accumulation of DNA DSBs following mitogen deprivation, possible by rescuing the level of origin firing.</p></sec><sec id="s2-8"><title>The role of <italic>p53</italic> loss in tumor development</title><p>To investigate whether the accumulation of DNA DSBs also operates <italic>in vivo</italic> to impede tumor growth, we studied retinoblastoma development in chimeric mice generated by blastocyst injection of <italic>Rb<sup>-/-</sup>Rbl2<sup>-/-</sup></italic>embryonic stem cells (ESCs) (<xref ref-type="bibr" rid="bib13">Dannenberg et al., 2000</xref>). Remarkably, murine retinoblastomas showed pronounced p53 and γ-H2AX staining (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). However, by sequencing, <italic>p53</italic> appeared wild-type in a separate series of seven tumors, indicating that in this model retinoblastomas did activate the DDR but could still colonize the entire eyeball. To study if <italic>p53</italic> inactivation accelerates tumorigenesis, we inactivated <italic>p53</italic> in <italic>Rb<sup>-/-</sup> Rbl2</italic><sup>-/-</sup> ESCs using CRISPR/Cas9-mediated gene disruption. However, no chimeric animals were obtained from <italic>Rb<sup>-/-</sup>Rbl2<sup>-/-</sup>p53<sup>-/-</sup></italic> ESCs, likely indicating that combined ablation of the Rb and p53 pathways is incompatible with embryonic development.</p><fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.37868.014</object-id><label>Figure 7.</label><caption><title>p53 inactivation promotes tumor growth <italic>in vivo</italic>.</title><p>(<bold>A</bold>) Examples of HE and immunohistochemical stainings for γ-H2AX and p53 of two retinoblastomas from <italic>Rb<sup>-/-</sup>Rbl2<sup>-/-</sup></italic> chimeric mice. (<bold>B</bold>) Tumor weight of <italic>Rb<sup>-/-</sup>Rbl2<sup>-/-</sup></italic> (black) and <italic>Rb<sup>-/-</sup>Rbl2<sup>-/-</sup>p53<sup>-/-</sup></italic> (red) teratomas 20 days after injection of ESCs in nude mice. Black dot marked with an asterisk (*) indicates the only tumor with high levels of infiltrating neutrophils. (<bold>C</bold>) Tail moments of <italic>Rb<sup>-/-</sup>Rbl2<sup>-/-</sup></italic> (black) and <italic>Rb<sup>-/-</sup>Rbl2<sup>-/-</sup>p53<sup>-/-</sup></italic> (red) teratomas plotted against the tumor weight. Spearman’s correlation coefficient between tail moment and tumor weight is −0.78. Black dot marked with an asterisk (*) indicates the only tumor with high levels of infiltrating neutrophils. One <italic>Rb<sup>-/-</sup>Rbl2<sup>-/-</sup>p53<sup>-/-</sup></italic> (red) teratoma could not be analyzed for DNA DSBs due to the small tissue size. For each teratoma, more than 50 cells were analyzed using the CASP software. (<bold>D</bold>) Examples of HE and immunohistochemical staining for γ-H2AX of <italic>Rb<sup>-/-</sup>Rbl2<sup>-/-</sup></italic> and <italic>Rb<sup>-/-</sup>Rbl2<sup>-/-</sup>p53<sup>-/-</sup></italic> teratomas. Scale bar is 50 µm. (<bold>E</bold>) Schematic model for how p53 inactivation reduces DNA DSBs in mitogen-deprived cells lacking the G1/S checkpoint. Cells that lost the G1/S phase checkpoint suffer from replication stress leading to DNA DSBs. Activation of p53 and p21<sup>Cip1</sup> inhibits CDK activity and thereby inhibits the firing of new origins leading to more DNA damage and establishment of the G2-like arrest (left panel). Inactivation of p53 and therefore its downstream protein p21<sup>Cip1</sup> increases CDK activity and allows origins to fire. Restored levels of origin firing rescues stalled forks, causing less DNA DSB formation and enabling proliferation (right panel).</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-37868-fig7-v2"/></fig><p>As an alternative <italic>in vivo</italic> readout, we injected <italic>Rb<sup>-/-</sup>Rbl2<sup>-/-</sup></italic> and <italic>Rb<sup>-/-</sup>Rbl2<sup>-/-</sup>p53<sup>-/-</sup></italic> mouse ESCs under the skin of nude mice. <italic>Rb<sup>-/-</sup>Rbl2<sup>-/-</sup></italic> ESCs developed a teratoma in 4 out of 6 mice; in contrast, <italic>Rb<sup>-/-</sup>Rbl2<sup>-/-</sup>p53<sup>-/-</sup></italic> ESCs developed a tumor in 6 out of 6 injected mice. On average the <italic>Rb<sup>-/-</sup>Rbl2<sup>-/-</sup>p53<sup>-/-</sup></italic> tumors were larger than <italic>Rb<sup>-/-</sup>Rbl2<sup>-/-</sup></italic> tumors (<xref ref-type="fig" rid="fig7">Figure 7B</xref>), although there is a 11% chance that the difference is accidental (p=0.1116, unpaired t-test). Teratomas of both genotypes mainly showed early neuronal differentiation and stained positive for the replication stress marker γ-H2AX (<xref ref-type="fig" rid="fig7">Figure 7C</xref>), suggesting that all tumors were suffering from replication stress. To assess the presence of DSBs, we performed a neutral comet assay on teratoma tissues. Three of the four <italic>Rb<sup>-/-</sup>Rbl2<sup>-/-</sup></italic> teratomas showed an increase in tail moment compared to the tail moments of <italic>Rb<sup>-/-</sup>Rbl2<sup>-/-</sup>p53<sup>-/-</sup></italic> teratomas (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). Of note, unlike the other tumors, the largest <italic>Rb<sup>-/-</sup>Rbl2<sup>-/-</sup></italic> tumor (marked with asterisk in <xref ref-type="fig" rid="fig7">Figure 7B,D</xref>) had high levels of infiltrating neutrophils, which possibly explains its bigger size as well as the low level of DNA DSBs.</p><p>Although the number of tumors was small, p53 knockout teratomas showed a trend towards lower levels of DSBs and accelerated tumor growth. Therefore, both our <italic>in vitro</italic> as well as <italic>in vivo</italic> data suggest that inactivation of p53 in G1/S checkpoint deficient cells contributes to tumorigenesis by reducing DNA DSBs (<xref ref-type="fig" rid="fig7">Figure 7E</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>We have previously shown that apoptosis-resistant MEFs that lack the G1/S phase checkpoint (TKO-Bcl2 MEFs) can undergo unscheduled S-phase entry. Here we show that they do so at the expense of severe replication stress and the accumulation of DNA DSBs, which ultimately causes G2-like cell cycle arrest. Inactivation of <italic>p53</italic> allowed mitogen-independent proliferation, which remarkably was not only associated with alleviated G2 arrest but also with reduced DNA breakage and restored origin firing. The firing of origins requires Cyclin-CDK activity (<xref ref-type="bibr" rid="bib20">Fragkos et al., 2015</xref>; <xref ref-type="bibr" rid="bib39">Méndez and Stillman, 2003</xref>). In mitogen-deprived TKO-Bcl2 MEFs, CDK activity was low due to the high levels of p21<sup>Cip1</sup> and p27<sup>Kip1</sup> explaining the low level of origin firing. It is therefore likely that upon p53 inactivation and therefore reduction of p21<sup>Cip1</sup>, CDK activity increased (<xref ref-type="bibr" rid="bib19">Foijer et al., 2005</xref>) and hence promoted origin firing. Consistently, we found that also genetic inactivation of p21<sup>Cip1</sup> restored origin firing and promoted proliferation of mitogen-deprived TKO-Bcl2 MEFs. Importantly, this phenomenon was not restricted to murine cells, but also observed in human RPE-1 cells: mitogen deprivation restricted origin firing and induced DNA breakage in G1/S-checkpoint-defective RPE-1s, and both could be reverted by inactivation of <italic>p53</italic>. However, for as yet unknown reasons, RPE-1 cells appeared highly sensitive to apoptosis and therefore the damage-reducing effect of <italic>p53</italic> loss did not translate into mitogen-independent proliferation.</p><p>While restored origin firing upon ablation of the p53/p21<sup>Cip1</sup> axis is mechanistically plausible, we have not directly proven that DNA breakage as a consequence of replication stress was prevented by increased origin firing. Related to this, an important question is whether <italic>p53</italic> inactivation reduced the formation of DNA breaks or stimulated DSB repair. Apart from its role as transcription factor, p53 has many transcription-independent functions, among which inhibition of DNA DSB repair by both non-homologous end joining (NHEJ) and homologous recombination (HR) (<xref ref-type="bibr" rid="bib40">Menon and Povirk, 2014</xref>; <xref ref-type="bibr" rid="bib57">Sengupta and Harris, 2005</xref>; <xref ref-type="bibr" rid="bib2">Akyüz et al., 2002</xref>; <xref ref-type="bibr" rid="bib17">Dudenhöffer et al., 1998</xref>). However, we show that KO of the p53 transcription target p21<sup>Cip1</sup> phenocopied the effects of KO of <italic>p53</italic> in TKO-Bcl2 MEFs, arguing against a transcription-independent role of p53 in suppressing DNA repair. Furthermore, increased DNA repair by NHEJ in G1 phase is unlikely as the levels of DSBs in serum-starved TKO-Bcl2-p53KO MEFs remained low when G1 entry was prevented by artificially arresting cells in M-phase. In this experiment it remains possible that an increase in HR activity during S/G2 phase contributed to less DNA breaks in mitogen-deprived p53KO MEFs. Also this possibility seems unlikely as the repair of HU-induced DSBs was not affected by p53 status. However, this experiment does not exclude the possibility that under mitogen-deprived conditions p53 suppressed DSB repair. With this restriction, we hypothesize that abrogation of <italic>p53</italic> reduced the formation of DNA breaks, rather than facilitated repair.</p><p>Novel roles of pRB and p53 are emerging but it is unclear to which extent they are implicated in suppression of cancer. Apart from its well documented role in cell cycle control, pRB has emerged as a multi-functional protein involved in a wide range of biological processes including chromatin architecture, cohesion, chromosome condensation during mitosis, DNA replication via interaction with replication components and involvement in DNA repair processes such as HR and NHEJ (<xref ref-type="bibr" rid="bib62">Vélez-Cruz and Johnson, 2017</xref>; <xref ref-type="bibr" rid="bib16">Dick and Rubin, 2013</xref>; <xref ref-type="bibr" rid="bib29">Huang et al., 2015</xref>). We suggest that these other functions of pRB do not play a role in the accumulation of DNA damage in Rb-deficient cells since we observed the same phenotype in Rb-<italic>proficient</italic> Cyclin D1 overexpressing RPE-1s. Thus, the accumulation of DNA DSBs in mitogen-deprived conditions can be attributed to loss of the G1/S phase checkpoint and not to other functions of the pRB protein or its family members.</p><p>It has been described that some ribosomal proteins have a function in the DNA damage response that is activated upon intrinsic replication stress and mediated through the Mdm2-p53 axis (<xref ref-type="bibr" rid="bib66">Xu et al., 2016</xref>). In addition, some ribosomal proteins act as a sensor for DNA damage and directly participate in the process of DNA repair. In this study, we cannot exclude an effect of p53 loss on the extra-ribosomal functions of these proteins. Also p53 has functions outside its canonical role in the DDR. Recently, a novel transcription-independent role for p53 in balancing replication homeostasis was reported. The p53 protein can bind to replication forks and facilitate replication fork restart in replication stress conditions (<xref ref-type="bibr" rid="bib53">Roy et al., 2018</xref>). Since we found a transcription-dependent role of p53 in suppressing origin firing, we hypothesize that the two different effects of p53 loss reflect different functions of p53 that operate side by side: dependent on the severity of replication stress, p53 facilitates replication fork restart and suppresses the firing of new origins.</p><p>Others have shown that disruption of the nucleotide pool can contribute to replication stress, DNA breakage and cell death in oncogene-expressing cells (<xref ref-type="bibr" rid="bib7">Bester et al., 2011</xref>; <xref ref-type="bibr" rid="bib50">Poli et al., 2012</xref>; <xref ref-type="bibr" rid="bib4">Beck et al., 2012</xref>; <xref ref-type="bibr" rid="bib47">Pfister et al., 2015</xref>). We were able to partially rescue replication speed in mitogen-deprived TKO-Bcl2 MEFs by exogenous supply of nucleosides. However, increased replication speed was not sufficient to overcome G2 arrest and to support normal cell cycle progression. Furthermore, we found that despite the capacity of TKO-Bcl2-p53KO MEFs to proliferate mitogen-independently, replication speed was still reduced. These observations indicate that another factor rather than the speed of DNA synthesis was critical for DNA breakage and G2 arrest in mitogen-deprived TKO-Bcl2 cells. As only origin firing but not replication speed was affected by <italic>p53</italic> status, we favor a scenario where restoration of origin firing upon inactivation of <italic>p53</italic>, given the involvement of p21<sup>Cip1</sup> likely as a result of restored CDK activity, suppressed DNA breakage and allowed mitogen-independent proliferation.</p><p>Loss of the Rb and p53 pathways frequently occur and co-occur in human tumors (<xref ref-type="bibr" rid="bib49">Polager and Ginsberg, 2009</xref>). The p53 gene is mutated in more than 50% of human cancer, and mutations in other genes that affect p53 function occur in many, if not all, tumors that retain a normal p53 gene (<xref ref-type="bibr" rid="bib45">Perri et al., 2016</xref>). In addition, most human tumors lack the G1/S phase checkpoint. For example many human tumors overexpress D-type cyclins and <italic>CCND1</italic> represents the second most frequently amplified locus in the human cancer genome (<xref ref-type="bibr" rid="bib28">Hosokawa and Arnold, 1998</xref>; <xref ref-type="bibr" rid="bib40">Menon and Povirk, 2014</xref>). Furthermore, evading apoptosis is one of the hallmarks of cancer and the anti-apoptotic gene Bcl2, which is used in this study to suppress apoptosis, is commonly overexpressed in many types of cancer, including renal, prostate, gastric, lung and colorectal cancer, neuroblastoma, non-Hodgkin’s lymphoma and acute and chronic leukemia (<xref ref-type="bibr" rid="bib21">Frenzel et al., 2009</xref>; <xref ref-type="bibr" rid="bib34">Kirkin et al., 2004</xref>). Thus, most tumor cells harbor the type of mutations used in this study. Whereas we can only speculate about the precise number of cancer types that harbor the exact combination of Rb, p53 and Bcl2 aberrations as used in this study, there are examples known. For example, approximately 90% of small cell lung cancer tumors have lost both p53 and Rb (<xref ref-type="bibr" rid="bib56">Sekido et al., 2003</xref>). Beside this, small cell lung tumors are also characterized by expression of Bcl2 (<xref ref-type="bibr" rid="bib32">Kaiser et al., 1996</xref>). Furthermore, human retinoblastoma originates from an intrinsic death-resistant precursor cell (<xref ref-type="bibr" rid="bib65">Xu et al., 2009</xref>), is characterized by mutations in the Rb gene and it is suggested that the p53 pathway is inactivated (<xref ref-type="bibr" rid="bib65">Xu et al., 2009</xref>; <xref ref-type="bibr" rid="bib37">Laurie et al., 2006</xref>). Although <italic>p53</italic> mutations are infrequent in human retinoblastomas, the p53 pathway may be intrinsically attenuated upon <italic>RB1</italic> loss by miR-24-mediated downregulation of p14<sup>ARF</sup> (<xref ref-type="bibr" rid="bib59">To et al., 2012</xref>) and by NANOS-mediated suppression of p53-activating kinases (<xref ref-type="bibr" rid="bib41">Miles et al., 2014</xref>). Other studies suggested that <italic>RB1</italic>-deficient retinal cells achieve attenuation of the p53 pathway by high expression of MDM2 and MDMX (<xref ref-type="bibr" rid="bib65">Xu et al., 2009</xref>; <xref ref-type="bibr" rid="bib37">Laurie et al., 2006</xref>), although a recent paper revealed critical p53-independent functions of high MDM2 expression (<xref ref-type="bibr" rid="bib51">Qi and Cobrinik, 2017</xref>).</p><p>In our chimeric mouse model of retinoblastoma, we found evidence for DNA damage, but loss of <italic>p53</italic> was not a requirement for development of eye-filling tumors. Unfortunately, we could not study the effect of <italic>p53</italic> loss, but using a hereditary retinoblastoma model, others reported a dramatic effect of <italic>p53</italic> inactivation. When <italic>Rb</italic> was conditionally inactivated in retinal progenitor cells in a <italic>p107<sup>-/-</sup></italic> background, non-invasive retinoblastomas developed with a penetrance of 60%. Upon additional inactivation of <italic>p53</italic>, aggressive, invasive bilateral retinoblastomas developed with 100% penetrance and reduced latency (<xref ref-type="bibr" rid="bib18">Dyer et al., 2005</xref>; <xref ref-type="bibr" rid="bib68">Zhang et al., 2004</xref>). Importantly, evidence has been obtained that murine retinoblastomas originate from an intrinsically death-resistant cell of origin (<xref ref-type="bibr" rid="bib12">Chen et al., 2004</xref>). We therefore propose that the tumor promoting effect of attenuated p53 activity was not due to abrogation of an apoptotic response but rather required for maintaining sufficient CDK activity to counteract the deleterious effects of replication stress. We obtained support for such tumor-promoting effect of <italic>p53</italic> ablation in an <italic>Rb<sup>-/-</sup>Rbl2<sup>-/-</sup> </italic>teratoma model: tumor size was inversely correlated with the level of DNA breaks and <italic>Rb<sup>-/-</sup>Rbl2<sup>-/-</sup>p53<sup>-/-</sup></italic> teratomas generally showed lower levels of DNA breaks than <italic>Rb<sup>-/-</sup>Rbl2<sup>-/-</sup> </italic>teratomas.</p><p>Finally, our results are likely related to intriguing observations that at least for some tumor types the outgrowth of early cancerous lesions is prohibited by activation of the DDR (<xref ref-type="bibr" rid="bib3">Bartkova et al., 2006</xref>). It has been suggested that oncogene activation can directly cause replication stress by hyper-stimulating DNA replication, which activates the ATR-Chk1 axis (<xref ref-type="bibr" rid="bib26">Hills and Diffley, 2014</xref>; <xref ref-type="bibr" rid="bib15">Di Micco et al., 2006</xref>; <xref ref-type="bibr" rid="bib24">Halazonetis et al., 2008</xref>). Furthermore, frequent DNA breakage associated with replication stress activates the complementary ATM-Chk2-p53 module that provides a strong barrier to proliferation by inducing apoptosis or permanent cell cycle arrest. It has therefore been suggested that activation of the DDR may explain the strong selective pressure for loss of p53 in human cancer (<xref ref-type="bibr" rid="bib24">Halazonetis et al., 2008</xref>). Rather than a direct consequence of oncogene activation, replication stress in our system was the consequence of the combination of Rb-protein deficiency (hyper-activating E2F transcription factors) and growth-restricting conditions (the absence of mitogenic signaling), leading to DNA breakage and activation of the DDR. Furthermore, we found loss of p53 not only abrogated cell cycle arrest and apoptosis, but also suppressed the induction of DNA damage itself, providing a novel mechanistic explanation for the frequent co-occurrence of p53 and pRb pathway inactivation in cancer.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type <break/>(species) or <break/>resource</th><th valign="top">Designation</th><th valign="top">Source or <break/>reference</th><th valign="top">Identifiers</th><th valign="top">Additional information</th></tr></thead><tbody><tr><td valign="top">Cell line <break/>(<italic>mus musculus</italic>) <break/>male</td><td valign="top">TKO-Bcl2 <break/>mouse embryonic <break/>fibroblasts (MEFs)</td><td valign="top">PMID:16338659</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Cell line <break/>(<italic>mus musculus</italic>) <break/>male</td><td valign="top">TKO-Bcl2-p53KO MEFs</td><td valign="top">This paper</td><td valign="top">N/A</td><td valign="top">Knockout of p53 in <break/>TKO-Bcl2 MEFs, <break/>described in the <break/>materials and methods</td></tr><tr><td valign="top">Cell line <break/>(<italic>mus musculus</italic>) <break/>male</td><td valign="top">TKO-p53RNAi MEFs</td><td valign="top">PMID:16338659</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Cell line <break/>(<italic>mus musculus</italic>) <break/>male</td><td valign="top">TKO-p53KO MEFs</td><td valign="top">This paper</td><td valign="top">N/A</td><td valign="top">Knockout of p53 in <break/>TKO MEFs, described in the <break/>materials and methods</td></tr><tr><td valign="top">cell line <break/>(<italic>mus musculus</italic>) <break/>male</td><td valign="top"><italic>Rb<sup>-/-</sup>Rbl2<sup>-/-</sup></italic> mESCs</td><td valign="top">PMID: 15574596</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Cell line <break/>(<italic>mus musculus</italic>) <break/>male</td><td valign="top"><italic>Rb<sup>-/-</sup>Rbl2<sup>-/-</sup>p53<sup>-/-</sup></italic> mESCs</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Knockout of p53 <break/>in <italic>Rb<sup>-/-</sup>Rbl2<sup>-/-</sup></italic>, described <break/>in the <break/>materials and methods</td></tr><tr><td valign="top">Cell line <break/>(<italic>homo sapiens</italic>) <break/>female</td><td valign="top">RPE-1 hTERT</td><td valign="top">ATCC</td><td valign="top">Cat# CRL-4000</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_4388">CVCL_4388</ext-link></td></tr><tr><td valign="top">Cell line <break/>(<italic>homo sapiens</italic>) <break/>female</td><td valign="top">TKO RPE-1s</td><td valign="top">This paper</td><td valign="top">N/A</td><td valign="top">Knockout of Rb, <break/>Rbl1 and Rbl2 in <break/>RPE-1-hTERT cells, <break/>described in material <break/>and methods</td></tr><tr><td valign="top">Cell line <break/>(<italic>homo sapiens</italic>) <break/>female</td><td valign="top">TKO-Bcl2 RPE-1s</td><td valign="top">This paper</td><td valign="top">N/A</td><td valign="top">Knockout of Rb, <break/>Rbl1, Rbl2 and <break/>overexpression of <break/>Bcl2 in RPE-1-hTERT <break/>cells, described in <break/>material and methods</td></tr><tr><td valign="top">Cell line <break/>(<italic>homo sapiens</italic>) <break/>female</td><td valign="top">TKO-Bcl2-p53KO RPE-1s</td><td valign="top">This paper</td><td valign="top">N/A</td><td valign="top">Knockout of Rb, Rbl1, <break/>Rbl2 and TP53 and <break/>overexpression of Bcl2 in <break/>RPE-1-hTERT cells, <break/>described in material and methods</td></tr><tr><td valign="top">Cell line <break/>(<italic>homo sapiens</italic>) <break/>female</td><td valign="top">CyclinD1 RPE-1s</td><td valign="top">This paper</td><td valign="top">N/A</td><td valign="top">Overexpression of <break/>non-degradable CyclinD1 (T286A) in RPE-1-hTERT cells, <break/>described in <break/>material and methods</td></tr><tr><td valign="top">Cell line <break/>(<italic>homo sapiens</italic>) <break/>female</td><td valign="top">CyclinD1-Bcl2 RPE-1s</td><td valign="top">This paper</td><td valign="top">N/A</td><td valign="top">Overexpression of <break/>non-degradable CyclinD1 (T286A) and Bcl2 in <break/>RPE-1-hTERT cells, <break/>described in material and methods</td></tr><tr><td valign="top">Cell line <break/>(<italic>homo sapiens</italic>) <break/>female</td><td valign="top">CyclinD1-Bcl2-p53KO <break/>RPE-1s</td><td valign="top">This paper</td><td valign="top">N/A</td><td valign="top">Knockout of TP53 and overexpression of <break/>non-degradable CyclinD1 (T286A) and Bcl2 in <break/>RPE-1-hTERT <break/>cells, described in <break/>material and methods</td></tr><tr><td valign="top">Antibody</td><td valign="top">Brdu <break/>(recognizing CldU)</td><td valign="top">Bioconnect</td><td valign="top">Cat# OBT0030G <break/>Clone BU1/75</td><td valign="top">RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_609567">AB_609567</ext-link> (1/500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">BrdU <break/>(recognizing IdU)</td><td valign="top">Becton Dickinson</td><td valign="top">Cat# 347580 Clone B44</td><td valign="top">RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10015219">AB_10015219</ext-link> (1/750)</td></tr><tr><td valign="top">Antibody</td><td valign="top">mouse p53</td><td valign="top">Abnova Corporation</td><td valign="top">Cat# MAB9657 Clone IMX25</td><td valign="top">RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10756365">AB_10756365</ext-link> <break/>(1/1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">mouse/ <break/>human p21</td><td valign="top">Santa Cruz</td><td valign="top">Cat# sc-397 C19</td><td valign="top">RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_632126">AB_632126</ext-link> (1/500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">p27</td><td valign="top">BD Transduction Laboratory</td><td valign="top">Cat# 554069</td><td valign="top">RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_395225">AB_395225</ext-link> (1/2000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">CDK4</td><td valign="top">Santa Cruz</td><td valign="top">Cat# sc-260 C22</td><td valign="top">RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_631219">AB_631219</ext-link> (1/2000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Actin</td><td valign="top">Santa Cruz</td><td valign="top">Cat# sc-1616</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_630836">AB_630836</ext-link> (1/1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">pChk1 Ser 317</td><td valign="top">Bethyl</td><td valign="top">Cat# A304-673A</td><td valign="top">RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2620868">AB_2620868</ext-link> (1/1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Chk1</td><td valign="top">Santa Cruz</td><td valign="top">Cat# sc-8408 G4</td><td valign="top">RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_627257">AB_627257</ext-link> (1/1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rb1</td><td valign="top">Santa Cruz</td><td valign="top">Cat# sc-50 C15</td><td valign="top">RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_632339">AB_632339</ext-link> <break/>(1/500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rbl1</td><td valign="top">Santa Cruz</td><td valign="top">Cat# sc-318 C18</td><td valign="top">RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2175428">AB_2175428</ext-link> (1/1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rbl2</td><td valign="top">Lab Vision</td><td valign="top">Cat# OP117 Clone AB1</td><td valign="top">RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_145257">AB_145257</ext-link> <break/>(1/1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Cyclin D1</td><td valign="top">Santa Cruz</td><td valign="top">Cat# sc-753 H296</td><td valign="top">RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2070433">AB_2070433</ext-link> (1/1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">human p53</td><td valign="top">BD Bioscience</td><td valign="top">Cat# 554293 <break/>Clone DO-1</td><td valign="top">RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_395348">AB_395348</ext-link> (1/500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Bcl2</td><td valign="top">Santa Cruz</td><td valign="top">Cat# sc-509</td><td valign="top">RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_626733">AB_626733</ext-link> (1/1000)</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">2'-deoxyadenosine <break/>monohydrate (dA)</td><td valign="top">Jena Bioscience</td><td valign="top">N-DN-1001</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">2'-deoxycytidine <break/>monohydrochloride (dC) <break/></td><td valign="top">Jena Bioscience</td><td valign="top">N-DN-6352</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">2'-deoxyguanosine <break/>monohydrate (dG)</td><td valign="top">Jena Bioscience</td><td valign="top">N-DN-1003</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">2'-deoxythymidine (dT)</td><td valign="top">Jena Bioscience</td><td valign="top">N-DN-6354</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Cell Player 96-well <break/>kinetic <break/>caspase-3/7 reagent</td><td valign="top">Essen Bioscience</td><td valign="top">Cat# 4440</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">CldU</td><td valign="top">Sigma</td><td valign="top">Cat# C6891-100mg</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">IdU</td><td valign="top">Sigma</td><td valign="top">Cat# I7125-5g</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">BrdU</td><td valign="top">Sigma</td><td valign="top">Cat# B5002-1G</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Hydroxyurea (HU)</td><td valign="top">Sigma</td><td valign="top">Cat# H8627</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Propidium <break/>Iodide (PI)</td><td valign="top">Thermo fisher scientific</td><td valign="top">Cat# P3566</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Puromycin</td><td valign="top">Sigma</td><td valign="top">Cat# P7255</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Penincillin/ <break/>Streptomycin</td><td valign="top">Gibco/Life technologies</td><td valign="top">Cat# 15140122</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Lipofectamine 2000</td><td valign="top">Invitrogen</td><td valign="top">Cat# 11668030</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Polybrene</td><td valign="top">Sigma</td><td valign="top">Cat# H9268</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Fluor-gel <break/>with TES buffer</td><td valign="top">Electron Microscopy Science</td><td valign="top">Cat# 17985–30</td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">GraphPad <break/>Prism 7</td><td valign="top">GraphPad Software</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/scientific-software/prism/">https://www.graphpad.com/</ext-link><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/scientific-software/prism/">scientific-software/prism/</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Adobe <break/>Photoshop CS6</td><td valign="top">Adobe</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.adobe.com/products/photoshop.html">https://www.adobe.com/products/photoshop.html</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Adobe Illustrator CS6</td><td valign="top">Adobe</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.adobe.com/products/illustrator.html">https://www.adobe.com/products/illustrator.html</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Image <break/>Studio Lite Ver. 4.0</td><td valign="top">LI-COR Biosciences</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.licor.com/bio/products/software/image_studio_lite/">https://www.licor.com/bio/products/software/image_studio_lite/</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">ImageJ</td><td valign="top"/><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://imagej.nih.gov/ij/download.html">https://imagej.nih.gov/ij/download.html</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">FlowJo <break/>software <break/>version 7.6.1</td><td valign="top">FlowJo, LCC</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.flowjo.com/solutions/flowjo/downloads">https://www.flowjo.com/solutions/flowjo/downloads</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Casplab</td><td valign="top">Casplab</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://casplab.com/download">http://casplab.com/download</ext-link></td><td valign="top"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cell culture</title><p>MEFs were isolated from chimeric embryos as previously described (<xref ref-type="bibr" rid="bib13">Dannenberg et al., 2000</xref>) and cultured in GMEM (Invitrogen), supplemented with 10% fetal calf serum (FCS), 0.1 mM nonessential amino acids (Invitrogen), 1 mM sodium pyruvate (Invitrogen), 100 µg/ml penicillin, 100 µg/ml streptomycin (Invitrogen) and 0.1 mM β-mercaptoeethanol (Merck) in the absence or presence of nucleoside (200 nM of Cytidine, Guanosine, Adenosine and Thymidine). TKO-Bcl2 overexpressing MEFs and TKO-p53RNAi were generated as described previously (<xref ref-type="bibr" rid="bib19">Foijer et al., 2005</xref>). CRISPR/Cas9 technology was used to inactive <italic>Trp53</italic> and <italic>Cdkn1a</italic>.</p><p>RPE-1 cells were kindly provided by J. Raaijmakers, who purchased the cells from ATCC. RPE-1 cells were cultured in DMEM/F12+GlutaMAX (Invitrogen), supplemented with 10% FCS, 100 µg/ml penicillin and 100 µg/ml streptomycin (Invitrogen). CRISPR/Cas9 technology was used to inactivate <italic>Rb</italic>, <italic>Rbl1</italic>, <italic>Rbl2 and TP53.</italic> Bcl2 cDNA and a non-degradable form of CylcinD1 cDNA was overexpressed using retroviral transfection.</p><p>For serum starvation experiments, cells were trypsinized and allowed to attach in the presence of serum for 4 hr. Subsequently, cells were washed with PBS and supplemented with serum free medium. To block progression into mitosis, cells were cultured in the presence of 250 ng/ml nocodazole. All cell lines have been tested for mycoplasma (PCR).</p></sec><sec id="s4-2"><title>Constructs, transfections, lentiviral and retroviral infections</title><p>The FUCCI constructs CSII-EF-MCS-mKO-hCdt1 (30/120) and CSII-EF-MCS-mAG-hGem (1/110) were kindly provided by A. Miyawaki (<xref ref-type="bibr" rid="bib55">Sakaue-Sawano et al., 2008</xref>). The 19-mer <italic>Trp53</italic> targeting sequence in pRetroSuper-RNAi-p53 is GTACATGTGTAATAGCTCC (<xref ref-type="bibr" rid="bib19">Foijer et al., 2005</xref>). Gene specific guideRNAs (mouse <italic>Trp53</italic>: TACCTCTCTTTGCGCTCCCT (<xref ref-type="bibr" rid="bib48">Platt et al., 2014</xref>); human <italic>RB</italic> TGAACGACATCTCATCT, human <italic>RBL1</italic> TTTCGTGAACGTATAGAA, human <italic>RBL2</italic> CGAGGTTGCTCCTCTTGA and human <italic>TP53</italic> GACGCTAGGATCTGACTG) were annealed to generate short double-strand DNA fragments with four base pairs overhang (CACC and AAAC) compatible with ligation into the <italic>BbsI</italic> digested Cas9/CRISPR px330-puro plasmid. The px330-p53 guideRNA vector was transfected into MEFs using Polyethylenimine (PEI) transfections. The px330-Rb-, px330-Rbl1-, px330-Rbl2 and px330-p53 guideRNA vectors were transfected into RPE-1 cells using Lipofectamine 2000 (Invitrogen). Afterwards, RPE-1 cells were selected with 10 ug/ml puromycin for two days. Two specific guideRNAs targeting the mouse <italic>Cdkn1a</italic> gene were AGCGCAGATTGGTCTTCT and CCCGCAGCCGTGACGACC with four base pairs overhang (CACC and AAAC) compatible with ligation into the in <italic>BmsbI</italic> digested pLentiCRISPR v2 vector. The 21-mer oligos in pLKO.1 targeting <italic>Ppat</italic> were: #1: CCACATGCTTATGTATGTATA and #2: CCGGAGAAATTGTAGAAATAT. Corresponding empty vector (EV) was used as control. Lentiviral plasmids were co-transfected with the helper plasmids pMDLgpRRE, VSV-G and pRSV-Rec into HEK293T cells by PEI transfection. A pBABE-puro retroviral vector encoding a non-degradable form of Cyclin D1 (T286A) was kindly provided by R. Agami (<xref ref-type="bibr" rid="bib1">Agami and Bernards, 2000</xref>). This retroviral vector was co-transfected with the helper plasmids puMCV-Gag pol MMLV and pCMV VSVG into HEK293T cells by PEI transfection. Both for lentiviral and retroviral transfections, forty-eight and sixty-two hours post transfection viral supernatants were filtered through 0.45 µm filter and used to infect MEFs in the presence of 4 µg/ml polybrene three times for 8–12 hr.</p></sec><sec id="s4-3"><title>Growth curves and caspase assay</title><p>The IncuCyte ZOOM instrument (Essen Bioscience) live cell imaging system was used to monitor cell growth. Cells were plated in a 96 Greiner micro clear plate and imaged every 4 hr. The default software parameters for a 96 well plate with a 10x objective were used for imaging. The IncuCyte software was used to calculate mean confluence from two non-overlapping bright phase images of each well.</p><p>The IncuCyte ZOOM instrument in combination with the Cell Player 96-well kinetic caspase-3/7 reagent (Essen Bioscience) were used to identify apoptosis by caspase 3/7 activity. The software was used to calculate mean green fluorescence from two non-overlapping fluorescent images of each well. Green fluorescent confluency was normalized to phase contrast confluency to determine apoptosis.</p></sec><sec id="s4-4"><title>Western blot analysis</title><p>Cells were harvested and subsequently lysed for 30 min in RIPA (25 mM Tris-HCl pH 7.6; 150 mM NaCl; 1% NP-40; 1% Sodiumdeoxycholate and 0.1% SDS) or ELB (150 mM NaCl; 50 mM Hepes pH7.5; 5 mM EDTA; 0.1% NP-40) containing protease inhibitors (Complete, Roche). Protein concentrations were measured using the BCA protein assay kit (Pierce).</p><p>The primary antibodies used were rabbit polyclonal phospho-Chk1 Ser317 (Bethyl), mouse monoclonal Chk1 (G4; Santa Cruz), goat polyclonal CDK4 (C22; Santa Cruz), rabbit polyclonal p21 (C19; Santa Cruz), mouse monoclonal p27 (BD Transduction Laboratory), goat polyclonal Rb (C15; Santa Cruz); rabbit polyclonal Rbl1 (C18; Santa Cruz), mouse monoclonal Rbl2 (CAS14; Lab Vision), mouse monoclonal p53 (IMX25; monosan; for detection of mouse p53), mouse monoclonal p53 (DO-1; BD Biosciences; for detection of human p53), γ-tubulin (GTU-88; Sigma), rabbit polyclonal Cyclin D1 (Santa Cruz; H296) and goat polyclonal CDK4 (C22; Santa Cruz). Secondary antibodies used were IR Dye 800CW Goat anti-Mouse IgG, Goat anti-Rabbit IgG and Donkey anti-Goat IgG (Licor) and HRP-conjugated Goat anti-Mouse and Goat anti-Rabbit (Dako).</p></sec><sec id="s4-5"><title>Immunofluorescence</title><p>For Rad51 and γ-H2AX immunofluorescence staining, cells were cultured on cover slides, washed with PBS and fixed for 5 min using 4% paraformaldehyde (Merck). Cells were permeabilized by 0.1% Triton-X100 (sigma) in PBS for 5 min. Subsequently, cells were washed three times using staining buffer (0.15% glycine (Merck), 0.5% Bovine Serum Albumine (BSA, Sigma) in PBS) and incubated for 1 hr at room temperature in staining buffer. Cells were incubated for 4 hr and 1 hr with primary and secondary antibodies, respectively.</p><p>For CldU and γ-H2AX immunofluorescence, cells were cultured on cover slides, incubated with CldU (100 mM) for 30 min, washed with PBS and fixed for 10 min using 70% EtOH. Cells were treated with MeOH for 5 min and incubated with 1.5 M HCl for 20 min. Subsequently, cells were blocked using PBS, 0.5% Tween, 0.25% BSA, 5% FCS for 30 min. Cells were incubated with primary and secondary antibodies for 2 hr and 1 hr, respectively in PBS, 0.5% Tween,0.25 BSA. Bleaching was prevented by Vectashield (Vetcor laboratories). The primary antibodies used were rat-anti-BrdU (Clone BU1/75, Novus Biologicals), rabbit polyclonal Rad51 (a gift from Prof. Roland Kanaar) and mouse monoclonal phosphorylated H2AX (Upstate) in 1:20, 1:2500 and 1:100 dilutions, respectively. Secondary antibodies used were Alexa 488-labeled Chicken-anti-Mouse, Alexa 568-labeled Goat-anti-Rabbit and Alexa 568-labeled Goat-anti-Rat antibodies (Molecular probes) and these were used in a 1:100 dilution. DNA was stained using To-Pro3 dye (Molecular probes).</p></sec><sec id="s4-6"><title>DNA fiber analysis</title><p>Cells were pulse-labelled with 25 μM CldU followed by 250 μM IdU for 20–40 min each. After labelling, cells were trypsinized and lysed in spreading buffer (200 mM Tris-Hcl pH 7.4, 50 mM EDTA and 0.5% SDS) before spreading on a microscope slide (Menzel-Gläser,Superfrost). Slides were fixed in methanol: acidic acid 3:1. Before immunodetection, slides were treated with 2.5 M HCl for 1 hr and 15 min. To detect CldU and IdU labelled tracts slide were incubated for 1 hr with rat-anti-Brdu (Clone BU1/75, Novus Biologicals; 1:500) and mouse-anti-BrdU (clone B44, Becton Diskinson; 1:750), respectively. Subsequently, slides were fixed with 4% paraformaldehyde for 10 min and incubated with Alexa 488-labeled goat-anti-mouse and Alexa 555-labeled goat-ant-rat (Molecular probes; 1:500) for 1 hr and 30 min. Pictures were taken with a Zeiss AxioObserver Z1 inverted microscope using a 63x lens equipped with a cooled Hamamatsu ORCA AG Black and White CCD camera and track lengths were analyzed with ImageJ software. Replication track lengths were calculated using the conversion factor 1 μm = 2.59 kb (<xref ref-type="bibr" rid="bib31">Jackson and Pombo, 1998</xref>). The 1-way ANOVA (nonparametric Kruskal-Wallis test) was used for statistical analyses.</p></sec><sec id="s4-7"><title>Time-lapse microscopy</title><p>Culture dishes were transferred to a heated stage (37°C) on a Zeiss Axiovert 200M inverted microscope. PhC (phase contrast) images (59 ms exposure) and fluorescent images (red: 500 ms and green 300 ms exposure) were captured with a 20x/0.25 Ph1 Achroplan objective in combination with 1.6 optovar every 30 min using a cooled Hamamatsu ORCA R2 Black and White CCD-camera and appropriate filter blocks to select specific fluorescence. Images were taken in 2 × 2 binning mode (672 × 512 pixels) and processed using AxioVision Rel. 4.7.2. software.</p></sec><sec id="s4-8"><title>Flow cytometry</title><p>MEFs cultured in the presence or absence of 10% FCS were labeled with BrdU (10 μM) for 1 hr, fixed in 70% EtOH and stained with Propidium Iodide (PI). Data acquisition was performed on a Beckman Coulter Cyan ADP and data analysis (cell cycle) was performed using FlowJo software version 7.6.1 (Tree Star, Ashland, OR, USA).</p></sec><sec id="s4-9"><title>Comet assay</title><p>Neutral comet assays were performed as described by Olive et al. (<xref ref-type="bibr" rid="bib42">Olive and Banáth, 2006</xref>). Pictures of individual cells were taken with a Zeiss AxioObserver Z1 inverted microscope equipped with a cooled Hamamatsu ORCA AG Black and White CCD camera and analyzed with CASP software (<ext-link ext-link-type="uri" xlink:href="http://www.casp.of.pl">http://www.casp.of.pl</ext-link>). The p-value was determined using 1-way ANOVA (nonparametric Kruskal-Wallis test).</p></sec><sec id="s4-10"><title>Generation of chimeric mice and teratomas</title><p>All experiments involving animals comply with local and international regulations and ethical guidelines (protocol 12026) and have been authorized by our local experimental animal committee at the Netherlands Cancer Institute (DEC-NKI). <italic>Rb<sup>-/-</sup>Rbl2<sup>-/-</sup></italic> ESCs were generated previously (<xref ref-type="bibr" rid="bib14">Dannenberg et al., 2004</xref>). These cells were injected into C57Bl/6 blastocysts (6 cells per blastocyst) to generate chimeric mice, which were monitored weekly for retinoblastoma development. <italic>Rb<sup>-/-</sup>Rbl2<sup>-/-</sup>p53<sup>-/-</sup></italic> ESCs were generated using CRISPR/Cas9 technology. One million cells of both cell lines were injected into the flank of Balb/c nude mice and tumors were harvested 20 days later.</p></sec><sec id="s4-11"><title>Histological and immunological analysis</title><p>Eyes and teratomas were removed immediately after euthanasia and fixed in 4% formaldehyde for at least 24 hr. For histological analysis, formaldehyde fixed tissues were embedded in paraffin, cut into 5 μm sections and stained with Hematoxilin and Eosin. The antibodies used were α-p53 (VectorLabs), α-p-ATM (Cell signaling), α−γ−H2AX (Cell signaling), α-p-CHK2 (Cell signaling) and α-p-ATM (Genetex).</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank A Miyawaki for CSII-EF-MCS-mKO-hCdt1 (30/120) and CSII-EF-MCS-mAG-hGem (1/110) and R Kanaar for rabbit polyclonal Rad51 antibody. We thank L Oomen and L Brocks for help with the microscopical visualization of the DNA fibers and help with time-lapse microscopy, T Harmsen for technical support and J-Y Song for analysis of immunohistochemical tissue stainings, T van Ravesteyn, S Bakker and N Wit for fruitful discussions. This work was supported by the Dutch Cancer Society (grants NKI 2007–3790 and NKI 2014–6702) and an EMBO short-term fellowship to TvH. (194-2011).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Validation, Investigation, Visualization, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Investigation, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con4"><p>Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con5"><p>Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con6"><p>Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con7"><p>Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con8"><p>Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con9"><p>Methodology, Writing—review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Supervision, Writing—review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Supervision, Funding acquisition, Visualization, Writing—original draft, Writing—review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other" id="fn1"><p>Animal experimentation: All experiments involving animals comply with local and international regulations and ethical guidelines (protocol 12026) and have been authorized by the local experimental animal ethical committee at the Netherlands Cancer Institute (DEC-NKI).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><object-id pub-id-type="doi">10.7554/eLife.37868.015</object-id><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-37868-transrepform-v2.docx"/></supplementary-material><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agami</surname> <given-names>R</given-names></name><name><surname>Bernards</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage</article-title><source>Cell</source><volume>102</volume><fpage>55</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)00010-6</pub-id><pub-id pub-id-type="pmid">10929713</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akyüz</surname> <given-names>N</given-names></name><name><surname>Boehden</surname> <given-names>GS</given-names></name><name><surname>Süsse</surname> <given-names>S</given-names></name><name><surname>Rimek</surname> <given-names>A</given-names></name><name><surname>Preuss</surname> <given-names>U</given-names></name><name><surname>Scheidtmann</surname> <given-names>KH</given-names></name><name><surname>Wiesmüller</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>DNA substrate dependence of p53-mediated regulation of double-strand break repair</article-title><source>Molecular and Cellular Biology</source><volume>22</volume><fpage>6306</fpage><lpage>6317</lpage><pub-id pub-id-type="doi">10.1128/MCB.22.17.6306-6317.2002</pub-id><pub-id pub-id-type="pmid">12167722</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartkova</surname> <given-names>J</given-names></name><name><surname>Rezaei</surname> <given-names>N</given-names></name><name><surname>Liontos</surname> <given-names>M</given-names></name><name><surname>Karakaidos</surname> <given-names>P</given-names></name><name><surname>Kletsas</surname> <given-names>D</given-names></name><name><surname>Issaeva</surname> <given-names>N</given-names></name><name><surname>Vassiliou</surname> <given-names>LV</given-names></name><name><surname>Kolettas</surname> <given-names>E</given-names></name><name><surname>Niforou</surname> <given-names>K</given-names></name><name><surname>Zoumpourlis</surname> <given-names>VC</given-names></name><name><surname>Takaoka</surname> <given-names>M</given-names></name><name><surname>Nakagawa</surname> <given-names>H</given-names></name><name><surname>Tort</surname> <given-names>F</given-names></name><name><surname>Fugger</surname> <given-names>K</given-names></name><name><surname>Johansson</surname> <given-names>F</given-names></name><name><surname>Sehested</surname> <given-names>M</given-names></name><name><surname>Andersen</surname> <given-names>CL</given-names></name><name><surname>Dyrskjot</surname> <given-names>L</given-names></name><name><surname>Ørntoft</surname> <given-names>T</given-names></name><name><surname>Lukas</surname> <given-names>J</given-names></name><name><surname>Kittas</surname> <given-names>C</given-names></name><name><surname>Helleday</surname> <given-names>T</given-names></name><name><surname>Halazonetis</surname> <given-names>TD</given-names></name><name><surname>Bartek</surname> <given-names>J</given-names></name><name><surname>Gorgoulis</surname> <given-names>VG</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints</article-title><source>Nature</source><volume>444</volume><fpage>633</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1038/nature05268</pub-id><pub-id pub-id-type="pmid">17136093</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname> <given-names>H</given-names></name><name><surname>Nähse-Kumpf</surname> <given-names>V</given-names></name><name><surname>Larsen</surname> <given-names>MS</given-names></name><name><surname>O'Hanlon</surname> <given-names>KA</given-names></name><name><surname>Patzke</surname> <given-names>S</given-names></name><name><surname>Holmberg</surname> <given-names>C</given-names></name><name><surname>Mejlvang</surname> <given-names>J</given-names></name><name><surname>Groth</surname> <given-names>A</given-names></name><name><surname>Nielsen</surname> <given-names>O</given-names></name><name><surname>Syljuåsen</surname> <given-names>RG</given-names></name><name><surname>Sørensen</surname> <given-names>CS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption</article-title><source>Molecular and Cellular Biology</source><volume>32</volume><fpage>4226</fpage><lpage>4236</lpage><pub-id pub-id-type="doi">10.1128/MCB.00412-12</pub-id><pub-id pub-id-type="pmid">22907750</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beroukhim</surname> <given-names>R</given-names></name><name><surname>Mermel</surname> <given-names>CH</given-names></name><name><surname>Porter</surname> <given-names>D</given-names></name><name><surname>Wei</surname> <given-names>G</given-names></name><name><surname>Raychaudhuri</surname> <given-names>S</given-names></name><name><surname>Donovan</surname> <given-names>J</given-names></name><name><surname>Barretina</surname> <given-names>J</given-names></name><name><surname>Boehm</surname> <given-names>JS</given-names></name><name><surname>Dobson</surname> <given-names>J</given-names></name><name><surname>Urashima</surname> <given-names>M</given-names></name><name><surname>Mc Henry</surname> <given-names>KT</given-names></name><name><surname>Pinchback</surname> <given-names>RM</given-names></name><name><surname>Ligon</surname> <given-names>AH</given-names></name><name><surname>Cho</surname> <given-names>YJ</given-names></name><name><surname>Haery</surname> <given-names>L</given-names></name><name><surname>Greulich</surname> <given-names>H</given-names></name><name><surname>Reich</surname> <given-names>M</given-names></name><name><surname>Winckler</surname> <given-names>W</given-names></name><name><surname>Lawrence</surname> <given-names>MS</given-names></name><name><surname>Weir</surname> <given-names>BA</given-names></name><name><surname>Tanaka</surname> <given-names>KE</given-names></name><name><surname>Chiang</surname> <given-names>DY</given-names></name><name><surname>Bass</surname> <given-names>AJ</given-names></name><name><surname>Loo</surname> <given-names>A</given-names></name><name><surname>Hoffman</surname> <given-names>C</given-names></name><name><surname>Prensner</surname> <given-names>J</given-names></name><name><surname>Liefeld</surname> <given-names>T</given-names></name><name><surname>Gao</surname> <given-names>Q</given-names></name><name><surname>Yecies</surname> <given-names>D</given-names></name><name><surname>Signoretti</surname> <given-names>S</given-names></name><name><surname>Maher</surname> <given-names>E</given-names></name><name><surname>Kaye</surname> <given-names>FJ</given-names></name><name><surname>Sasaki</surname> <given-names>H</given-names></name><name><surname>Tepper</surname> <given-names>JE</given-names></name><name><surname>Fletcher</surname> <given-names>JA</given-names></name><name><surname>Tabernero</surname> <given-names>J</given-names></name><name><surname>Baselga</surname> <given-names>J</given-names></name><name><surname>Tsao</surname> <given-names>MS</given-names></name><name><surname>Demichelis</surname> <given-names>F</given-names></name><name><surname>Rubin</surname> <given-names>MA</given-names></name><name><surname>Janne</surname> <given-names>PA</given-names></name><name><surname>Daly</surname> <given-names>MJ</given-names></name><name><surname>Nucera</surname> <given-names>C</given-names></name><name><surname>Levine</surname> <given-names>RL</given-names></name><name><surname>Ebert</surname> <given-names>BL</given-names></name><name><surname>Gabriel</surname> <given-names>S</given-names></name><name><surname>Rustgi</surname> <given-names>AK</given-names></name><name><surname>Antonescu</surname> <given-names>CR</given-names></name><name><surname>Ladanyi</surname> <given-names>M</given-names></name><name><surname>Letai</surname> <given-names>A</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name><name><surname>Loda</surname> <given-names>M</given-names></name><name><surname>Beer</surname> <given-names>DG</given-names></name><name><surname>True</surname> <given-names>LD</given-names></name><name><surname>Okamoto</surname> <given-names>A</given-names></name><name><surname>Pomeroy</surname> <given-names>SL</given-names></name><name><surname>Singer</surname> <given-names>S</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Sellers</surname> <given-names>WR</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The landscape of somatic copy-number alteration across human cancers</article-title><source>Nature</source><volume>463</volume><fpage>899</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1038/nature08822</pub-id><pub-id pub-id-type="pmid">20164920</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertoli</surname> <given-names>C</given-names></name><name><surname>Skotheim</surname> <given-names>JM</given-names></name><name><surname>de Bruin</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Control of cell cycle transcription during G1 and S phases</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>14</volume><fpage>518</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1038/nrm3629</pub-id><pub-id pub-id-type="pmid">23877564</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bester</surname> <given-names>AC</given-names></name><name><surname>Roniger</surname> <given-names>M</given-names></name><name><surname>Oren</surname> <given-names>YS</given-names></name><name><surname>Im</surname> <given-names>MM</given-names></name><name><surname>Sarni</surname> <given-names>D</given-names></name><name><surname>Chaoat</surname> <given-names>M</given-names></name><name><surname>Bensimon</surname> <given-names>A</given-names></name><name><surname>Zamir</surname> <given-names>G</given-names></name><name><surname>Shewach</surname> <given-names>DS</given-names></name><name><surname>Kerem</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Nucleotide deficiency promotes genomic instability in early stages of cancer development</article-title><source>Cell</source><volume>145</volume><fpage>435</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.03.044</pub-id><pub-id pub-id-type="pmid">21529715</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bianchi</surname> <given-names>V</given-names></name><name><surname>Pontis</surname> <given-names>E</given-names></name><name><surname>Reichard</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis</article-title><source>The Journal of Biological Chemistry</source><volume>261</volume><fpage>16037</fpage><lpage>16042</lpage><pub-id pub-id-type="pmid">3536919</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bieging</surname> <given-names>KT</given-names></name><name><surname>Mello</surname> <given-names>SS</given-names></name><name><surname>Attardi</surname> <given-names>LD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Unravelling mechanisms of p53-mediated tumour suppression</article-title><source>Nature Reviews Cancer</source><volume>14</volume><fpage>359</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1038/nrc3711</pub-id><pub-id pub-id-type="pmid">24739573</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bunz</surname> <given-names>F</given-names></name><name><surname>Dutriaux</surname> <given-names>A</given-names></name><name><surname>Lengauer</surname> <given-names>C</given-names></name><name><surname>Waldman</surname> <given-names>T</given-names></name><name><surname>Zhou</surname> <given-names>S</given-names></name><name><surname>Brown</surname> <given-names>JP</given-names></name><name><surname>Sedivy</surname> <given-names>JM</given-names></name><name><surname>Kinzler</surname> <given-names>KW</given-names></name><name><surname>Vogelstein</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Requirement for p53 and p21 to sustain G2 arrest after DNA damage</article-title><source>Science</source><volume>282</volume><fpage>1497</fpage><lpage>1501</lpage><pub-id pub-id-type="doi">10.1126/science.282.5393.1497</pub-id><pub-id pub-id-type="pmid">9822382</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burkhart</surname> <given-names>DL</given-names></name><name><surname>Sage</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Cellular mechanisms of tumour suppression by the retinoblastoma gene</article-title><source>Nature Reviews Cancer</source><volume>8</volume><fpage>671</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/nrc2399</pub-id><pub-id pub-id-type="pmid">18650841</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>D</given-names></name><name><surname>Livne-bar</surname> <given-names>I</given-names></name><name><surname>Vanderluit</surname> <given-names>JL</given-names></name><name><surname>Slack</surname> <given-names>RS</given-names></name><name><surname>Agochiya</surname> <given-names>M</given-names></name><name><surname>Bremner</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Cell-specific effects of RB or RB/p107 loss on retinal development implicate an intrinsically death-resistant cell-of-origin in retinoblastoma</article-title><source>Cancer Cell</source><volume>5</volume><fpage>539</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2004.05.025</pub-id><pub-id pub-id-type="pmid">15193257</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dannenberg</surname> <given-names>JH</given-names></name><name><surname>van Rossum</surname> <given-names>A</given-names></name><name><surname>Schuijff</surname> <given-names>L</given-names></name><name><surname>te Riele</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Ablation of the retinoblastoma gene family deregulates G(1) control causing immortalization and increased cell turnover under growth-restricting conditions</article-title><source>Genes &amp; Development</source><volume>14</volume><fpage>3051</fpage><lpage>3064</lpage><pub-id pub-id-type="doi">10.1101/gad.847700</pub-id><pub-id pub-id-type="pmid">11114893</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dannenberg</surname> <given-names>JH</given-names></name><name><surname>Schuijff</surname> <given-names>L</given-names></name><name><surname>Dekker</surname> <given-names>M</given-names></name><name><surname>van der Valk</surname> <given-names>M</given-names></name><name><surname>te Riele</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Tissue-specific tumor suppressor activity of retinoblastoma gene homologs p107 and p130</article-title><source>Genes &amp; Development</source><volume>18</volume><fpage>2952</fpage><lpage>2962</lpage><pub-id pub-id-type="doi">10.1101/gad.322004</pub-id><pub-id pub-id-type="pmid">15574596</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Micco</surname> <given-names>R</given-names></name><name><surname>Fumagalli</surname> <given-names>M</given-names></name><name><surname>Cicalese</surname> <given-names>A</given-names></name><name><surname>Piccinin</surname> <given-names>S</given-names></name><name><surname>Gasparini</surname> <given-names>P</given-names></name><name><surname>Luise</surname> <given-names>C</given-names></name><name><surname>Schurra</surname> <given-names>C</given-names></name><name><surname>Garre'</surname> <given-names>M</given-names></name><name><surname>Nuciforo</surname> <given-names>PG</given-names></name><name><surname>Bensimon</surname> <given-names>A</given-names></name><name><surname>Maestro</surname> <given-names>R</given-names></name><name><surname>Pelicci</surname> <given-names>PG</given-names></name><name><surname>d'Adda di Fagagna</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication</article-title><source>Nature</source><volume>444</volume><fpage>638</fpage><lpage>642</lpage><pub-id pub-id-type="doi">10.1038/nature05327</pub-id><pub-id pub-id-type="pmid">17136094</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dick</surname> <given-names>FA</given-names></name><name><surname>Rubin</surname> <given-names>SM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Molecular mechanisms underlying RB protein function</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>14</volume><fpage>297</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1038/nrm3567</pub-id><pub-id pub-id-type="pmid">23594950</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dudenhöffer</surname> <given-names>C</given-names></name><name><surname>Rohaly</surname> <given-names>G</given-names></name><name><surname>Will</surname> <given-names>K</given-names></name><name><surname>Deppert</surname> <given-names>W</given-names></name><name><surname>Wiesmüller</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Specific mismatch recognition in Heteroduplex intermediates by p53 suggests a role in fidelity control of homologous recombination</article-title><source>Molecular and Cellular Biology</source><volume>18</volume><fpage>5332</fpage><lpage>5342</lpage><pub-id pub-id-type="doi">10.1128/MCB.18.9.5332</pub-id><pub-id pub-id-type="pmid">9710617</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dyer</surname> <given-names>MA</given-names></name><name><surname>Rodriguez-Galindo</surname> <given-names>C</given-names></name><name><surname>Wilson</surname> <given-names>MW</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Use of preclinical models to improve treatment of retinoblastoma</article-title><source>PLoS Medicine</source><volume>2</volume><elocation-id>e332</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.0020332</pub-id><pub-id pub-id-type="pmid">16231976</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foijer</surname> <given-names>F</given-names></name><name><surname>Wolthuis</surname> <given-names>RM</given-names></name><name><surname>Doodeman</surname> <given-names>V</given-names></name><name><surname>Medema</surname> <given-names>RH</given-names></name><name><surname>te Riele</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Mitogen requirement for cell cycle progression in the absence of pocket protein activity</article-title><source>Cancer Cell</source><volume>8</volume><fpage>455</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2005.10.021</pub-id><pub-id pub-id-type="pmid">16338659</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fragkos</surname> <given-names>M</given-names></name><name><surname>Ganier</surname> <given-names>O</given-names></name><name><surname>Coulombe</surname> <given-names>P</given-names></name><name><surname>Méchali</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>DNA replication origin activation in space and time</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>16</volume><fpage>360</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1038/nrm4002</pub-id><pub-id pub-id-type="pmid">25999062</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frenzel</surname> <given-names>A</given-names></name><name><surname>Grespi</surname> <given-names>F</given-names></name><name><surname>Chmelewskij</surname> <given-names>W</given-names></name><name><surname>Villunger</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Bcl2 family proteins in carcinogenesis and the treatment of cancer</article-title><source>Apoptosis</source><volume>14</volume><fpage>584</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1007/s10495-008-0300-z</pub-id><pub-id pub-id-type="pmid">19156528</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gassmann</surname> <given-names>MG</given-names></name><name><surname>Stanzel</surname> <given-names>A</given-names></name><name><surname>Werner</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Growth factor-regulated expression of enzymes involved in nucleotide biosynthesis: a novel mechanism of growth factor action</article-title><source>Oncogene</source><volume>18</volume><fpage>6667</fpage><lpage>6676</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1203120</pub-id><pub-id pub-id-type="pmid">10597272</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorgoulis</surname> <given-names>VG</given-names></name><name><surname>Vassiliou</surname> <given-names>LV</given-names></name><name><surname>Karakaidos</surname> <given-names>P</given-names></name><name><surname>Zacharatos</surname> <given-names>P</given-names></name><name><surname>Kotsinas</surname> <given-names>A</given-names></name><name><surname>Liloglou</surname> <given-names>T</given-names></name><name><surname>Venere</surname> <given-names>M</given-names></name><name><surname>Ditullio</surname> <given-names>RA</given-names></name><name><surname>Kastrinakis</surname> <given-names>NG</given-names></name><name><surname>Levy</surname> <given-names>B</given-names></name><name><surname>Kletsas</surname> <given-names>D</given-names></name><name><surname>Yoneta</surname> <given-names>A</given-names></name><name><surname>Herlyn</surname> <given-names>M</given-names></name><name><surname>Kittas</surname> <given-names>C</given-names></name><name><surname>Halazonetis</surname> <given-names>TD</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions</article-title><source>Nature</source><volume>434</volume><fpage>907</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1038/nature03485</pub-id><pub-id pub-id-type="pmid">15829965</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halazonetis</surname> <given-names>TD</given-names></name><name><surname>Gorgoulis</surname> <given-names>VG</given-names></name><name><surname>Bartek</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>An oncogene-induced DNA damage model for cancer development</article-title><source>Science</source><volume>319</volume><fpage>1352</fpage><lpage>1355</lpage><pub-id pub-id-type="doi">10.1126/science.1140735</pub-id><pub-id pub-id-type="pmid">18323444</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname> <given-names>D</given-names></name><name><surname>Weinberg</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The hallmarks of cancer</article-title><source>Cell</source><volume>100</volume><fpage>57</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81683-9</pub-id><pub-id pub-id-type="pmid">10647931</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hills</surname> <given-names>SA</given-names></name><name><surname>Diffley</surname> <given-names>JF</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>DNA replication and oncogene-induced replicative stress</article-title><source>Current Biology</source><volume>24</volume><fpage>R435</fpage><lpage>R444</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2014.04.012</pub-id><pub-id pub-id-type="pmid">24845676</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname> <given-names>A</given-names></name><name><surname>Dowdy</surname> <given-names>SF</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Regulation of G(1) cell-cycle progression by oncogenes and tumor suppressor genes</article-title><source>Current Opinion in Genetics &amp; Development</source><volume>12</volume><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/S0959-437X(01)00263-5</pub-id><pub-id pub-id-type="pmid">11790554</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hosokawa</surname> <given-names>Y</given-names></name><name><surname>Arnold</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human Cancer cells: analysis of allele-specific expression</article-title><source>Genes, Chromosomes and Cancer</source><volume>22</volume><fpage>66</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1098-2264(199805)22:1&lt;66::AID-GCC9&gt;3.0.CO;2-5</pub-id><pub-id pub-id-type="pmid">9591636</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>PH</given-names></name><name><surname>Cook</surname> <given-names>R</given-names></name><name><surname>Mittnacht</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>RB in DNA repair</article-title><source>Oncotarget</source><volume>6</volume><fpage>20746</fpage><lpage>20747</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.5234</pub-id><pub-id pub-id-type="pmid">26309077</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname> <given-names>SP</given-names></name><name><surname>Bartek</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The DNA-damage response in human biology and disease</article-title><source>Nature</source><volume>461</volume><fpage>1071</fpage><lpage>1078</lpage><pub-id pub-id-type="doi">10.1038/nature08467</pub-id><pub-id pub-id-type="pmid">19847258</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname> <given-names>DA</given-names></name><name><surname>Pombo</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Replicon clusters are stable units of chromosome structure: evidence that nuclear organization contributes to the efficient activation and propagation of S phase in human cells</article-title><source>The Journal of Cell Biology</source><volume>140</volume><fpage>1285</fpage><lpage>1295</lpage><pub-id pub-id-type="doi">10.1083/jcb.140.6.1285</pub-id><pub-id pub-id-type="pmid">9508763</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaiser</surname> <given-names>U</given-names></name><name><surname>Schilli</surname> <given-names>M</given-names></name><name><surname>Haag</surname> <given-names>U</given-names></name><name><surname>Neumann</surname> <given-names>K</given-names></name><name><surname>Kreipe</surname> <given-names>H</given-names></name><name><surname>Kogan</surname> <given-names>E</given-names></name><name><surname>Havemann</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Expression of bcl-2--protein in small cell lung cancer</article-title><source>Lung Cancer</source><volume>15</volume><fpage>31</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/0169-5002(96)00568-5</pub-id><pub-id pub-id-type="pmid">8865121</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karimian</surname> <given-names>A</given-names></name><name><surname>Ahmadi</surname> <given-names>Y</given-names></name><name><surname>Yousefi</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage</article-title><source>DNA Repair</source><volume>42</volume><fpage>63</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.dnarep.2016.04.008</pub-id><pub-id pub-id-type="pmid">27156098</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirkin</surname> <given-names>V</given-names></name><name><surname>Joos</surname> <given-names>S</given-names></name><name><surname>Zörnig</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The role of Bcl-2 family members in tumorigenesis</article-title><source>Biochimica et Biophysica Acta (BBA) - Molecular Cell Research</source><volume>1644</volume><fpage>229</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2003.08.009</pub-id><pub-id pub-id-type="pmid">14996506</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klusmann</surname> <given-names>I</given-names></name><name><surname>Rodewald</surname> <given-names>S</given-names></name><name><surname>Müller</surname> <given-names>L</given-names></name><name><surname>Friedrich</surname> <given-names>M</given-names></name><name><surname>Wienken</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Schulz-Heddergott</surname> <given-names>R</given-names></name><name><surname>Dobbelstein</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>p53 activity results in DNA replication fork processivity</article-title><source>Cell Reports</source><volume>17</volume><fpage>1845</fpage><lpage>1857</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.10.036</pub-id><pub-id pub-id-type="pmid">27829155</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koç</surname> <given-names>A</given-names></name><name><surname>Wheeler</surname> <given-names>LJ</given-names></name><name><surname>Mathews</surname> <given-names>CK</given-names></name><name><surname>Merrill</surname> <given-names>GF</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Hydroxyurea arrests DNA replication by a mechanism that preserves basal dNTP pools</article-title><source>Journal of Biological Chemistry</source><volume>279</volume><fpage>223</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1074/jbc.M303952200</pub-id><pub-id pub-id-type="pmid">14573610</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laurie</surname> <given-names>NA</given-names></name><name><surname>Donovan</surname> <given-names>SL</given-names></name><name><surname>Shih</surname> <given-names>CS</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Mills</surname> <given-names>N</given-names></name><name><surname>Fuller</surname> <given-names>C</given-names></name><name><surname>Teunisse</surname> <given-names>A</given-names></name><name><surname>Lam</surname> <given-names>S</given-names></name><name><surname>Ramos</surname> <given-names>Y</given-names></name><name><surname>Mohan</surname> <given-names>A</given-names></name><name><surname>Johnson</surname> <given-names>D</given-names></name><name><surname>Wilson</surname> <given-names>M</given-names></name><name><surname>Rodriguez-Galindo</surname> <given-names>C</given-names></name><name><surname>Quarto</surname> <given-names>M</given-names></name><name><surname>Francoz</surname> <given-names>S</given-names></name><name><surname>Mendrysa</surname> <given-names>SM</given-names></name><name><surname>Guy</surname> <given-names>RK</given-names></name><name><surname>Marine</surname> <given-names>JC</given-names></name><name><surname>Jochemsen</surname> <given-names>AG</given-names></name><name><surname>Dyer</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Inactivation of the p53 pathway in retinoblastoma</article-title><source>Nature</source><volume>444</volume><fpage>61</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1038/nature05194</pub-id><pub-id pub-id-type="pmid">17080083</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname> <given-names>AJ</given-names></name><name><surname>Oren</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The first 30 years of p53: growing ever more complex</article-title><source>Nature Reviews Cancer</source><volume>9</volume><fpage>749</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1038/nrc2723</pub-id><pub-id pub-id-type="pmid">19776744</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Méndez</surname> <given-names>J</given-names></name><name><surname>Stillman</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Perpetuating the double helix: molecular machines at eukaryotic DNA replication origins</article-title><source>BioEssays</source><volume>25</volume><fpage>1158</fpage><lpage>1167</lpage><pub-id pub-id-type="doi">10.1002/bies.10370</pub-id><pub-id pub-id-type="pmid">14635251</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menon</surname> <given-names>V</given-names></name><name><surname>Povirk</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Involvement of p53 in the repair of DNA double strand breaks: multifaceted roles of p53 in homologous recombination repair (HRR) and non-homologous end joining (NHEJ)</article-title><source>Sub-Cellular Biochemistry</source><volume>85</volume><fpage>321</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1007/978-94-017-9211-0_17</pub-id><pub-id pub-id-type="pmid">25201202</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miles</surname> <given-names>WO</given-names></name><name><surname>Korenjak</surname> <given-names>M</given-names></name><name><surname>Griffiths</surname> <given-names>LM</given-names></name><name><surname>Dyer</surname> <given-names>MA</given-names></name><name><surname>Provero</surname> <given-names>P</given-names></name><name><surname>Dyson</surname> <given-names>NJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Post-transcriptional gene expression control by NANOS is up-regulated and functionally important in pRb-deficient cells</article-title><source>The EMBO Journal</source><volume>33</volume><fpage>2201</fpage><lpage>2215</lpage><pub-id pub-id-type="doi">10.15252/embj.201488057</pub-id><pub-id pub-id-type="pmid">25100735</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olive</surname> <given-names>PL</given-names></name><name><surname>Banáth</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The comet assay: a method to measure DNA damage in individual cells</article-title><source>Nature Protocols</source><volume>1</volume><fpage>23</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1038/nprot.2006.5</pub-id><pub-id pub-id-type="pmid">17406208</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olivier</surname> <given-names>M</given-names></name><name><surname>Hollstein</surname> <given-names>M</given-names></name><name><surname>Hainaut</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>TP53 mutations in human cancers: origins, consequences, and clinical use</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>2</volume><elocation-id>a001008</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a001008</pub-id><pub-id pub-id-type="pmid">20182602</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perna</surname> <given-names>D</given-names></name><name><surname>Fagà</surname> <given-names>G</given-names></name><name><surname>Verrecchia</surname> <given-names>A</given-names></name><name><surname>Gorski</surname> <given-names>MM</given-names></name><name><surname>Barozzi</surname> <given-names>I</given-names></name><name><surname>Narang</surname> <given-names>V</given-names></name><name><surname>Khng</surname> <given-names>J</given-names></name><name><surname>Lim</surname> <given-names>KC</given-names></name><name><surname>Sung</surname> <given-names>WK</given-names></name><name><surname>Sanges</surname> <given-names>R</given-names></name><name><surname>Stupka</surname> <given-names>E</given-names></name><name><surname>Oskarsson</surname> <given-names>T</given-names></name><name><surname>Trumpp</surname> <given-names>A</given-names></name><name><surname>Wei</surname> <given-names>CL</given-names></name><name><surname>Müller</surname> <given-names>H</given-names></name><name><surname>Amati</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Genome-wide mapping of Myc binding and gene regulation in serum-stimulated fibroblasts</article-title><source>Oncogene</source><volume>31</volume><fpage>1695</fpage><lpage>1709</lpage><pub-id pub-id-type="doi">10.1038/onc.2011.359</pub-id><pub-id pub-id-type="pmid">21860422</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perri</surname> <given-names>F</given-names></name><name><surname>Pisconti</surname> <given-names>S</given-names></name><name><surname>Della Vittoria Scarpati</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>P53 mutations and cancer: a tight linkage</article-title><source>Annals of Translational Medicine</source><volume>4</volume><elocation-id>522</elocation-id><pub-id pub-id-type="doi">10.21037/atm.2016.12.40</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petermann</surname> <given-names>E</given-names></name><name><surname>Helleday</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Pathways of mammalian replication fork restart</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>11</volume><fpage>683</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1038/nrm2974</pub-id><pub-id pub-id-type="pmid">20842177</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfister</surname> <given-names>SX</given-names></name><name><surname>Markkanen</surname> <given-names>E</given-names></name><name><surname>Jiang</surname> <given-names>Y</given-names></name><name><surname>Sarkar</surname> <given-names>S</given-names></name><name><surname>Woodcock</surname> <given-names>M</given-names></name><name><surname>Orlando</surname> <given-names>G</given-names></name><name><surname>Mavrommati</surname> <given-names>I</given-names></name><name><surname>Pai</surname> <given-names>CC</given-names></name><name><surname>Zalmas</surname> <given-names>LP</given-names></name><name><surname>Drobnitzky</surname> <given-names>N</given-names></name><name><surname>Dianov</surname> <given-names>GL</given-names></name><name><surname>Verrill</surname> <given-names>C</given-names></name><name><surname>Macaulay</surname> <given-names>VM</given-names></name><name><surname>Ying</surname> <given-names>S</given-names></name><name><surname>La Thangue</surname> <given-names>NB</given-names></name><name><surname>D'Angiolella</surname> <given-names>V</given-names></name><name><surname>Ryan</surname> <given-names>AJ</given-names></name><name><surname>Humphrey</surname> <given-names>TC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Inhibiting WEE1 selectively kills histone H3K36me3-Deficient cancers by dNTP starvation</article-title><source>Cancer Cell</source><volume>28</volume><fpage>557</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2015.09.015</pub-id><pub-id pub-id-type="pmid">26602815</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Platt</surname> <given-names>RJ</given-names></name><name><surname>Chen</surname> <given-names>S</given-names></name><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Yim</surname> <given-names>MJ</given-names></name><name><surname>Swiech</surname> <given-names>L</given-names></name><name><surname>Kempton</surname> <given-names>HR</given-names></name><name><surname>Dahlman</surname> <given-names>JE</given-names></name><name><surname>Parnas</surname> <given-names>O</given-names></name><name><surname>Eisenhaure</surname> <given-names>TM</given-names></name><name><surname>Jovanovic</surname> <given-names>M</given-names></name><name><surname>Graham</surname> <given-names>DB</given-names></name><name><surname>Jhunjhunwala</surname> <given-names>S</given-names></name><name><surname>Heidenreich</surname> <given-names>M</given-names></name><name><surname>Xavier</surname> <given-names>RJ</given-names></name><name><surname>Langer</surname> <given-names>R</given-names></name><name><surname>Anderson</surname> <given-names>DG</given-names></name><name><surname>Hacohen</surname> <given-names>N</given-names></name><name><surname>Regev</surname> <given-names>A</given-names></name><name><surname>Feng</surname> <given-names>G</given-names></name><name><surname>Sharp</surname> <given-names>PA</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>CRISPR-Cas9 knockin mice for genome editing and cancer modeling</article-title><source>Cell</source><volume>159</volume><fpage>440</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.09.014</pub-id><pub-id pub-id-type="pmid">25263330</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polager</surname> <given-names>S</given-names></name><name><surname>Ginsberg</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>p53 and E2f: partners in life and death</article-title><source>Nature Reviews Cancer</source><volume>9</volume><fpage>738</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1038/nrc2718</pub-id><pub-id pub-id-type="pmid">19776743</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poli</surname> <given-names>J</given-names></name><name><surname>Tsaponina</surname> <given-names>O</given-names></name><name><surname>Crabbé</surname> <given-names>L</given-names></name><name><surname>Keszthelyi</surname> <given-names>A</given-names></name><name><surname>Pantesco</surname> <given-names>V</given-names></name><name><surname>Chabes</surname> <given-names>A</given-names></name><name><surname>Lengronne</surname> <given-names>A</given-names></name><name><surname>Pasero</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>dNTP pools determine fork progression and origin usage under replication stress</article-title><source>The EMBO Journal</source><volume>31</volume><fpage>883</fpage><lpage>894</lpage><pub-id pub-id-type="doi">10.1038/emboj.2011.470</pub-id><pub-id pub-id-type="pmid">22234185</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname> <given-names>DL</given-names></name><name><surname>Cobrinik</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation</article-title><source>Oncogene</source><volume>36</volume><fpage>1760</fpage><lpage>1769</lpage><pub-id pub-id-type="doi">10.1038/onc.2016.350</pub-id><pub-id pub-id-type="pmid">27748758</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinhardt</surname> <given-names>HC</given-names></name><name><surname>Schumacher</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The p53 network: cellular and systemic DNA damage responses in aging and cancer</article-title><source>Trends in Genetics</source><volume>28</volume><fpage>128</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2011.12.002</pub-id><pub-id pub-id-type="pmid">22265392</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname> <given-names>S</given-names></name><name><surname>Tomaszowski</surname> <given-names>K-H</given-names></name><name><surname>Luzwick</surname> <given-names>JW</given-names></name><name><surname>Park</surname> <given-names>S</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Murphy</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Suppresses mutagenic RAD52 and polθ pathways by orchestrating DNA replicationrestart homeostasis</article-title><source>eLife</source><volume>7</volume><elocation-id>e31723</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.31723</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sage</surname> <given-names>J</given-names></name><name><surname>Mulligan</surname> <given-names>GJ</given-names></name><name><surname>Attardi</surname> <given-names>LD</given-names></name><name><surname>Miller</surname> <given-names>A</given-names></name><name><surname>Chen</surname> <given-names>S</given-names></name><name><surname>Williams</surname> <given-names>B</given-names></name><name><surname>Theodorou</surname> <given-names>E</given-names></name><name><surname>Jacks</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization</article-title><source>Genes &amp; Development</source><volume>14</volume><fpage>3037</fpage><lpage>3050</lpage><pub-id pub-id-type="doi">10.1101/gad.843200</pub-id><pub-id pub-id-type="pmid">11114892</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakaue-Sawano</surname> <given-names>A</given-names></name><name><surname>Kurokawa</surname> <given-names>H</given-names></name><name><surname>Morimura</surname> <given-names>T</given-names></name><name><surname>Hanyu</surname> <given-names>A</given-names></name><name><surname>Hama</surname> <given-names>H</given-names></name><name><surname>Osawa</surname> <given-names>H</given-names></name><name><surname>Kashiwagi</surname> <given-names>S</given-names></name><name><surname>Fukami</surname> <given-names>K</given-names></name><name><surname>Miyata</surname> <given-names>T</given-names></name><name><surname>Miyoshi</surname> <given-names>H</given-names></name><name><surname>Imamura</surname> <given-names>T</given-names></name><name><surname>Ogawa</surname> <given-names>M</given-names></name><name><surname>Masai</surname> <given-names>H</given-names></name><name><surname>Miyawaki</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Visualizing spatiotemporal dynamics of multicellular cell-cycle progression</article-title><source>Cell</source><volume>132</volume><fpage>487</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.12.033</pub-id><pub-id pub-id-type="pmid">18267078</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sekido</surname> <given-names>Y</given-names></name><name><surname>Fong</surname> <given-names>KM</given-names></name><name><surname>Minna</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Molecular genetics of lung cancer</article-title><source>Annual Review of Medicine</source><volume>54</volume><fpage>73</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1146/annurev.med.54.101601.152202</pub-id><pub-id pub-id-type="pmid">12471176</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sengupta</surname> <given-names>S</given-names></name><name><surname>Harris</surname> <given-names>CC</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>p53: traffic cop at the crossroads of DNA repair and recombination</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>6</volume><fpage>44</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1038/nrm1546</pub-id><pub-id pub-id-type="pmid">15688066</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherr</surname> <given-names>CJ</given-names></name><name><surname>McCormick</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The RB and p53 pathways in cancer</article-title><source>Cancer Cell</source><volume>2</volume><fpage>103</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/S1535-6108(02)00102-2</pub-id><pub-id pub-id-type="pmid">12204530</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>To</surname> <given-names>KH</given-names></name><name><surname>Pajovic</surname> <given-names>S</given-names></name><name><surname>Gallie</surname> <given-names>BL</given-names></name><name><surname>Thériault</surname> <given-names>BL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Regulation of p14ARF expression by miR-24: a potential mechanism compromising the p53 response during retinoblastoma development</article-title><source>BMC Cancer</source><volume>12</volume><elocation-id>69</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2407-12-69</pub-id><pub-id pub-id-type="pmid">22336108</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuduri</surname> <given-names>S</given-names></name><name><surname>Tourrière</surname> <given-names>H</given-names></name><name><surname>Pasero</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Defining replication origin efficiency using DNA fiber assays</article-title><source>Chromosome Research</source><volume>18</volume><fpage>91</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1007/s10577-009-9098-y</pub-id><pub-id pub-id-type="pmid">20039120</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Harn</surname> <given-names>T</given-names></name><name><surname>Foijer</surname> <given-names>F</given-names></name><name><surname>van Vugt</surname> <given-names>M</given-names></name><name><surname>Banerjee</surname> <given-names>R</given-names></name><name><surname>Yang</surname> <given-names>F</given-names></name><name><surname>Oostra</surname> <given-names>A</given-names></name><name><surname>Joenje</surname> <given-names>H</given-names></name><name><surname>te Riele</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Loss of rb proteins causes genomic instability in the absence of mitogenic signaling</article-title><source>Genes &amp; Development</source><volume>24</volume><fpage>1377</fpage><lpage>1388</lpage><pub-id pub-id-type="doi">10.1101/gad.580710</pub-id><pub-id pub-id-type="pmid">20551164</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vélez-Cruz</surname> <given-names>R</given-names></name><name><surname>Johnson</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The retinoblastoma (RB) Tumor suppressor: pushing back against genome instability on multiple fronts</article-title><source>International Journal of Molecular Sciences</source><volume>18</volume><fpage>1776</fpage><pub-id pub-id-type="doi">10.3390/ijms18081776</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Weinberg</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2007">2007</year><chapter-title>pRb and control of the cell cycle clock</chapter-title><source>The Biology of Cancer</source><publisher-loc>New York</publisher-loc><publisher-name>Garland Science</publisher-name><fpage>255</fpage><lpage>307</lpage></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname> <given-names>AB</given-names></name><name><surname>Schumacher</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>p53 in the DNA-Damage-Repair Process</article-title><source>Cold Spring Harbor Perspectives in Medicine</source><volume>6</volume><elocation-id>a026070</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a026070</pub-id><pub-id pub-id-type="pmid">27048304</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>XL</given-names></name><name><surname>Fang</surname> <given-names>Y</given-names></name><name><surname>Lee</surname> <given-names>TC</given-names></name><name><surname>Forrest</surname> <given-names>D</given-names></name><name><surname>Gregory-Evans</surname> <given-names>C</given-names></name><name><surname>Almeida</surname> <given-names>D</given-names></name><name><surname>Liu</surname> <given-names>A</given-names></name><name><surname>Jhanwar</surname> <given-names>SC</given-names></name><name><surname>Abramson</surname> <given-names>DH</given-names></name><name><surname>Cobrinik</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Retinoblastoma has properties of a cone precursor tumor and depends upon cone-specific MDM2 signaling</article-title><source>Cell</source><volume>137</volume><fpage>1018</fpage><lpage>1031</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.03.051</pub-id><pub-id pub-id-type="pmid">19524506</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>X</given-names></name><name><surname>Xiong</surname> <given-names>X</given-names></name><name><surname>Sun</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The role of ribosomal proteins in the regulation of cell proliferation, tumorigenesis, and genomic integrity</article-title><source>Science China Life Sciences</source><volume>59</volume><fpage>656</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1007/s11427-016-0018-0</pub-id><pub-id pub-id-type="pmid">27294833</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zachos</surname> <given-names>G</given-names></name><name><surname>Rainey</surname> <given-names>MD</given-names></name><name><surname>Gillespie</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects</article-title><source>The EMBO Journal</source><volume>22</volume><fpage>713</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1093/emboj/cdg060</pub-id><pub-id pub-id-type="pmid">12554671</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Schweers</surname> <given-names>B</given-names></name><name><surname>Dyer</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The first knockout mouse model of retinoblastoma</article-title><source>Cell Cycle</source><volume>3</volume><fpage>950</fpage><lpage>957</lpage><pub-id pub-id-type="doi">10.4161/cc.3.7.1002</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.37868.017</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Schlacher</surname><given-names>Katharina</given-names></name><role>Reviewing Editor</role><aff><institution>UT MD Anderson Cancer Center</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;Loss of p53 suppresses replication-stress-induced DNA breakage in G1/S checkpoint deficient cells&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Guest Reviewing Editor and Jessica Tyler as the Senior Editor. The following individual involved in review of your submission has agreed to reveal his identity: David Johnson (Reviewer #2).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>In the presented work, the authors demonstrate the unexpected finding that inactivation of p53 in Rb triple-knockout mouse cells leads to a decrease in DNA damage, rather than an expected increase. This decrease in DNA damage correlates with increased origin firing with p53 inactivation, and allows the serum-starved cells to re-enter the cell cycle and proliferate, which could explain the frequent co-inactivation of Rb and p53 in human tumors.</p><p>All three reviewers agree that the manuscript is of potential interest. However, there are two major concerns that are necessary to be addressed before publication.</p><p>Essential revisions:</p><p>1) The biological relevance is unclear at this point as the authors use an unusual mouse system and TKO cells do not naturally occur. Therefore, a physiologically more relevant system needs to be tested. As one example, the authors could express p53 or p21 in Rb null human cancer cells and show rescue/reversion of key-conclusions of the study including origin firing, DNA damage and survival.</p><p>2) There appear to be conflicting effects of serum versus serum starvation, whereby serum starvation leads to reduced DNA damage yet increased apoptosis (Figure 1B), while the presence of serum in the same genetic system leads to increased DNA damage (Figure 3B). Similarly, it has been reported that p53 defects lead to a decrease rather than an increase in origin firing in cells irrespective of whether they are human, mouse, transformed, primary, mutant or null p53 (Roy et al., 2018). Therefore, these seeming conflicts between serum vs. non-serum conditions and whether the effect is dependent specifically on Rb or TKO need to be experimentally addressed.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.37868.018</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The biological relevance is unclear at this point as the authors use an unusual mouse system and TKO cells do not naturally occur. Therefore, a physiologically more relevant system needs to be tested. As one example, the authors could express p53 or p21 in Rb null human cancer cells and show rescue/reversion of key-conclusions of the study including origin firing, DNA damage and survival.</p></disp-quote><p>Indeed, cancer cells lacking all three pocket proteins (“TKO cells”) do not seem to occur naturally. However, it is known that the majority of human tumors lack the G1/S phase checkpoint and insensitivity to antigrowth signals has been identified as a hallmark of cancer. Rather than full knockout of critical effectors, abrogation of the G1/S checkpoint may also result from a combination of reduced levels of effectors (e.g. a pocket protein) and increased levels of inhibitors of G1 arrest (e.g. Cyclin D1, E2F1). Our TKO system provides a clean way to study the consequences of such a G1/S checkpoint loss, but we believe other ways of abrogating the G1/S checkpoint will have similar consequences. Indeed, we show that our findings were not dependent specifically on loss of Rb and other pocket proteins but resulted from loss of the G1/S checkpoint in general: overexpression of Cyclin D1 had similar effects as loss of the Rb family members (Figure 6). Moreover, these effects were observed in the human RPE-1 cell line, showing they were not a peculiarity of the TKO mouse embryonic fibroblast system (Figure 6).</p><p>Overexpression of Cyclin D1 is biologically relevant since comprehensive analysis of many human cancer types revealed that the gene encoding Cyclin D1 represents the second most frequently amplified locus in the human cancer genome (Beroukhim et al., 2010). In addition, in many human tumors overexpression of D type cyclins takes place in the absence of detectable genomic alterations (Hosokawa et al., 1998).</p><p>Modification: In our opinion, the experiments done in human cells and the Cyclin D experiment corroborates the physiological relevance of our findings. See Results section “Also in human cells inactivation of p53 is associated with reduced DNA DSBs”.</p><p>While the suggested experiment may indeed complement our findings, it should be noted that reintroduction of p53 is notoriously difficult as tumor cells are often adapted to abrogation of p53 activity and hence stop proliferating upon reactivation of p53.</p><disp-quote content-type="editor-comment"><p>2) There appear to be conflicting effects of serum versus serum starvation, whereby serum starvation leads to reduced DNA damage yet increased apoptosis (Figure 1B), while the presence of serum in the same genetic system leads to increased DNA damage (Figure 3B). Similarly, it has been reported that p53 defects lead to a decrease rather than an increase in origin firing in cells irrespective of whether they are human, mouse, transformed, primary, mutant or null p53 (Roy et al., 2018). Therefore, these seeming conflicts between serum vs. non-serum conditions and whether the effect is dependent specifically on Rb or TKO need to be experimentally addressed.</p></disp-quote><p>We do not believe there is a discrepancy between Figures 1B and 3B. It is true that p53KO reduced DNA damage in TKO-Bcl2 cells upon serum starvation (Figure 3B), while this appeared to be accompanied with higher levels of cell death (Figure 1B). However, the very low level of cell death in TKO-Bcl2 cells despite the high level of damage is caused by the fact that these cells do not proliferate but become arrested in a G2-like state (Figure 1C). Apparently, the proliferation of TKO-Bcl2-p53KO cells in the absence of serum comes at the price of low levels of (p53-independent) cell death, whereas TKO-Bcl2 cells respond to serum deprivation by cell cycle arrest rendering them insensitive to apoptotic cell death.</p><p>Furthermore, we observed that inactivation of p53 and p21<sup>Cip1</sup> in TKO-Bcl2 MEFs slightly increased DNA damage in the presence of serum compared to TKO-Bcl2 MEFs. We hypothesized this was due to the regulatory function of p53 in the DNA damage response; upon inactivation of p53 or p21<sup>Cip1</sup>, cells tolerate a higher level of DNA damage irrespective of the culture conditions. The critical point though we wanted to make here is that serum deprivation did <italic>not</italic> increase DNA damage in TKO-Bcl2-p53KO or TKO-Bcl2-p21KO MEFs while a clear increase in DNA damage was seen in TKO-Bcl2 MEFs.</p><p>Modification: We have now better explained this observation in the subsection “p53/p21<sup>Cip1</sup> knockout suppresses DSBs formation”, stressing the difference between basal levels of DSBs and induction of DSBs by mitogen deprivation.</p><p>We subsequently showed that reduced induction of DNA damage in serum-starved TKO-Bcl2-p53KO cells was accompanied by increased origin firing. Indeed, this may conflict with the recent publication of Roy et al. (2018). Roy et al. identified a novel role for p53 in balancing replication homeostasis. In wild type cells experiencing replication stress, p53 binds to replication forks and facilitates replication fork restart by recruitment of MLL3 and MRE11. Upon knockout or mutation of p53, MLL3 and MRE11 are not recruited and mutagenic RAD52 and POLθ pathways can act at reversed forks and induce genomic instability. In addition, the authors report a clear decrease inthe level of origin firing in p53 KO MEFs compared to wild type MEFs in the presence of a low dose of hydroxyurea (HU).</p><p>At first glance, the latter indeed seems opposite to our findings. By comparing the observations and experimental setups, we envisage several explanations for this discrepancy.</p><p>1) Roy et al. clearly showed that the new function of p53 in regulating DNA homeostasis is transcription-independent, whereas we found that the role of p53 in suppressing origin firing is dependent on its downstream transcription factor p21<sup>Cip1</sup>. The two effects therefore rely on different functions of p53 that may operate side by side: it doesn’t seem without logic that upon replication stress, p53 operates twofold to properly process stalled replication forks and to suppress new origin firing.</p><p>2) Nevertheless, Roy et al. clearly observed reduced origin firing upon ablation of p53. In their experiments they apply first color labeling (green) of nascent DNA followed by second color labeling (red) in the presence of HU, that is continuous replication stress. Their subsequent experiments make a strong case for p53 to promote replication fork restart. Indeed in the absence of p53, the level of stalled forks, that is green only fibers, increase. Apparently many of the green fibers become immediately stalled upon HU treatment, that is without a trace of red, and cannot resume without p53. Would it be possible then that many newly initiated forks become immediately stalled and cannot resume, and hence remain invisible as a red fiber? However, a third alternative seems more likely:</p><p>3) The differential effect of p53 ablation on origin firing may also be related to the level of replication stress induced. Whereas Roy et al. used low doses of HU to induce replication stress, we cultured cells in the absence of mitogens, a condition inducing stringent replication stress observed by the drastic reduction of the replication fork speed. As suggested by Roy et al., low levels of replication stress induced replication fork stalling, but not replication fork collapse, that is DNA DSBs. In contrast, high levels of replication stress induced DSB formation. Thus, at low doses of HU, replication forks stall and p53 operates to protect and properly restart these forks. At high levels of replication stress, stalled replication forks get broken and activate p53 to suppress new origin firing. Hence, ablation of p53 increases new origin firing, which may help to rescue stalled forks preventing further breakage.</p><p>To study this hypothesis, we exposed cells to a low dose of HU (300 µM; similar to the dose used by Roy et al.) and found no induction of DNA DSBs. In contrast, high levels of HU (2 mM) did induce DNA DSBs (see Figure 5—figure supplement 2A). Furthermore, consistent with Roy et al., p53 KO reduced origin firing after exposure to la low dose of HU, while at a high dose of HU, the level of origin firing was not changed upon loss of p53. (See Figure 5—figure supplement 2B). Based on this observation, we believe the severity of replication stress dictates the outcome of p53 ablation.</p><p>Modification: We describe these new findings in the revised manuscript. See the Results section “Reduced DNA breakage by p53 knockout is associated with increased origin firing”, the Discussion, fourth paragraph, and Figure 5—figure supplement 2.</p></body></sub-article></article>